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Components of the T cell mediated immune response 
 
A major task of the immune system is to protect us against diseases caused by 
microorganisms. Additionally, the immune system regulates the maintenance of 
homeostasis by the disposal of dysregulated (e.g., tumor) and dead cells. The specific 
immune response plays an important role in these processes. Recognition of antigens 
from bacteria and viruses leads to an immune response dedicated to eradication of 
the infectious agent. Key players in the specific immune system are the B and T cells. 
T cells interact with their T cell receptors (TCRs) with an antigenic peptide in the 
context of a molecule of the major histocompatibility complex (MHC) proteins on the 
surface of an antigen presenting cell (APC). The specificity of this interaction is the 
result of different MHC molecules (6-12) and the innumerable amount of different 
TCRs (hundreds of millions or more) that each individual expresses, out of the even 
greater number of possible molecules. When the antigen constitutes a ‘danger’ signal 
for the T cell, the signaling pathway is activated and ultimately this leads to 
activation of the T cell.1 Activation of the T cell is dependent on co-stimulation of 
ligand-receptor pairs on the T cell and the APC where they contact in the 
immunological synapse, such as CD28-B7, CD40-CD40L, and CD134-CD134L.2,3 Two 
types of T cells can be distinguished, depending on the presence of the CD4 or CD8 
co-receptor, i.e., CD4+ T cells and CD8+ T cells. The former recognize peptides 
derived merely from extracellular antigens presented by MHC class II molecules and 
the latter recognize peptides from processed intracellular antigens presented by 
MHC class I molecules. CD4+ T cells, that can be roughly divided into Th1, Th2, and 
Treg cells, are involved in macrophage and B cell activation and immune regulation. 
CD8+ T cells are cytotoxic T cells, destroying the infected or dysregulated cell that 
presents the recognized peptide. 
 
 
Autoimmune disease 
 
An inappropriate immune response against self tissue can result in an autoimmune 
disease, such as insulin-dependent diabetes mellitus (IDDM), rheumatoid arthritis 
(RA), and multiple sclerosis (MS). This unwanted autoaggressive immune response 
results from breaking of tolerance to self antigens, that can be due to molecular 
mimicry between microbial and self peptides.4 Alternatively, posttranslational 
modification that can alter a T cell epitope, has been implicated in the onset of 
autoimmune disease.5 Although the autoantigen is not always known, association 
between autoimmune diseases, such as ankylosing spondylitis, IDDM, RA, and MS, 
and the expression of particular MHC alleles has been documented.6 This 
autoimmune disease associated MHC molecule may present the autoantigenic 
peptide that is not presented by a disease non-associated MHC molecule. 
 
One of the best characterized experimental animal models for autoimmune diseases 
is experimental autoimmune encephalomyelitis (EAE), resembling human MS.7 
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Lewis rats develop EAE after immunization with guinea pig myelin basic protein 
(gpMBP) or peptides thereof, in combination with complete Freund’s adjuvant 
(CFA). Recognition of epitopes of this protein ultimately leads to destruction of the 
myelin sheath, causing paralysis. About twelve days after immunization in the hind 
foot pads, paralysis becomes apparent in the tail end and progresses towards the 
hind limbs, back and fore limbs. Contrary to human MS, paralysis in EAE disappears 
after five to six days. In severe cases the expiratory muscles are affected, frequently 
leading to death. Candidate (auto)antigens to which the T cell response is directed 
include MBP, myelin oligodendrocyte glycoprotein, and proteolipid protein.8 Amino 
acid sequence 72-85 of gpMBP (numbering according to the bovine MBP, sequence 
QKSQRSQDENPV) is the major immunogenic epitope that is presented by the rat 
MHC class II RT1.BL molecule.9 The T cell mediated character of EAE is 
demonstrated by the adoptive transfer in naive animals of CD4+ T cells that 
recognize this epitope.10,11 
 
 
Altered peptide ligands 
 
Full activation of the T cell through the T cell receptor results in proliferation and a 
wide range of effector functions, such as cytokine secretion. However, engagement of 
the MHC-peptide complex with the TCR does not necessarily lead to T cell 
activation. Partial T cell activation or complete absence of T cell activation may be the 
result of modifications in the antigenic peptide as in altered peptide ligands (APLs),12 
that are recognized by the TCR. Different types of APLs can be distinguished, 
depending on the degree of T cell activation.13,14 Super agonists induce full T cell 
activation at lower concentrations than the original peptide. Weak agonists require a 
higher concentration than the original peptide. Partial agonists cannot induce full T 
cell activation, but instead induce some T cell functions, such as cytokine secretion 
without proliferation. An active state of T cell unresponsiveness is seen after anergy 
induction.15 Antagonists do not activate the T cell, but inhibit activation by an 
agonistic peptide. 
 
 
Immunotherapy 
 
Altered peptide ligands have been succesfully used for immunotherapy of 
experimental autoimmune diseases, such as EAE.16-25 APLs are created by small 
modifications to peptide amino acid residues that contact the TCR,12 for example by 
exchange of an amino acid residue for a different one. It is therefore anticipated that 
these APLs exert their effect (e.g., antagonism) on the T cell specific for the unaltered 
T cell epitope. In the case that the target T cell is an autoreactive T cell, an 
autoimmune response could be modulated. A second type of APL has also been 
defined. Instead of modulating the autoreactive T cell directly, they induce a new T 
cell population, that can exert T cell immunomodulatory effect by deviation of the 
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immune response (e.g., skewing of the Th1 response towards Th2)24 and/or by the T 
cell regulatory effect of this new T cell population itself (also called bystander 
suppression).24,26,27 
 
Successful application of APLs in experimental animal models prompted the 
initiation of clinical studies, addressing the safety and efficacy of APL 
immunotherapy in MS patients.28,29 The APL was a modified form of human 
immunodominant epitope MBP83-99. These phase II clinical trials were terminated 
before completion, because of increased disease severity or the occurrence of 
hypersensitivity reactions. Both these effects might be inherently associated to the 
mechanism by which the APL alters T cell activation. This indicates the importance 
of understanding the consequences of peptide modification for the outcome of T cell 
activation and the (side) effects thereof. 
 
 
T cell activation and peptide discrimination 
 
Although studied extensively, it is still unclear how binding of an MHC-peptide 
complex to a T cell receptor results in activation of the T cell. Different models were 
proposed that describe this initial triggering of T cell activation. In summary, 
according to di- or multimerization models, MHC-peptide-TCR interaction brings 
together TCRs with TCR associated co-stimulatory and signaling molecules, while 
the raft association and the kinetic-segregation model propose that a single MHC-
peptide-TCR complex can cause lipid raft association and close contact between the 
TCR and signaling molecules.30 Unfortunately, none of the competing models 
provide a general explanation for the mechanism of TCR triggering.30 
 
Differential phosphorylation, as one of the early events of T cell triggering, was 
shown to occur for altered peptides, differing in their stimulatory capacity.31 
Functional or structural dissimilarities in the MHC-agonist/antagonist-TCR 
complexes leading to these differential signaling events, however, are difficult to 
define. Attempts to relate the affinity of the MHC-peptide complex for the TCR to the 
degree of T cell activation were carried out in the past. Indeed, relationships of a 
higher TCR affinity of an MHC-agonist peptide complex compared to an MHC-
antagonist peptide complex were found (e.g., reference 32). However, also data have 
been published that could not confirm this correlation, showing similar affinities for 
agonist and antagonists (e.g., reference 33). Even a reverse relationship of an 
antagonist having a higher affinity than a weak agonist has been reported.34 
Subsequently, the kinetics of MHC-peptide complexes binding to isolated TCR 
molecules were examined extensively. Unfortunately, also half life and dissociation 
rate of the MHC-peptide complex and the TCR were not always related to the 
outcome of T cell activation.35,36 It was concluded that there might be a relationship 
between affinity or half life/dissociation rate in individual cases, but that this is not 
generally applicable.36-38 
General introduction 
11 
Alternatively, differences in the peptide structure of an agonist and an antagonist 
peptide, and conformational adaptation of the TCR to these differences have been 
studied. Small and large adjustments occurred in that part of the TCR that contacted 
the peptide in response to peptide modifications.33,36,39 These structural adaptations, 
however, were not transduced through the TCR to the signaling machinery, and the 
mechanism by which this leads to discrimination between peptides with different 
stimulatory capacities, is still unclear.33,36 Therefore, insight into the structural 
elements of this ternary interaction is of great importance. 
 
 
MHC structure 
 
MHC class I molecules are expressed on all nucleated cells, while MHC class II 
molecules are restricted to professional APCs. Due to different antigen processing 
machineries, MHC class I molecules present peptides originating from cytosolic 
proteins, whereas MHC class II molecules merely bind peptides derived from 
antigens that entered the cell via endocytosis. MHC molecules are cell surface 
glycoproteins, of which several structures have been determined by X-ray 
crystallography.40 Although MHC class I and class II molecules are composed of 
different subunits, they are closely related in three-dimensional structure. The 
peptide binding cleft of both MHC types is formed by two α helices with underneath 
an antiparallel β-pleated sheet (Figures 1 and 2). The extracellular structure is 
completed by two constant domains. In MHC class I molecules both α helices and the 
β sheet are formed by the α chain. The constant domains are formed by the α and β 
chains and the α chain spans the membrane. In MHC class II molecules the α and β 
chain each form an α helix and together they form the β sheet. The constant domains 
consist of the α and β chain and both chains are anchored in the membrane. In MHC 
class I molecules the peptide binding cleft is closed at both ends, but in MHC class II 
molecules the cleft is open. 
 
 
MHC-peptide binding 
 
The peptide is bound in an extended conformation in the MHC molecule. In MHC 
class I molecules, peptides are restricted in length (8-10 amino acids) due to the 
closed ends of the binding groove.41,42 The peptide is mainly bound by hydrogen 
bonds at the N- and the C-terminus, the unbound middle of the peptide commonly 
displaying a kink.43,44 Peptides bound to MHC class II molecules are not restricted in 
length (usually 11-25 amino acids).45-47 MHC class II molecules bind peptides in a 
polyproline type II twist, in which the side chains in the peptide differ approximately 
130° from the preceding amino acid.48 Consequently, amino acid side chains at 
certain positions in the peptide protrude from the MHC surface and others are 
buried in the MHC binding pockets formed by the α helix and the β sheet. 
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Binding of peptides to MHC molecules consists of interactions that are conserved 
throughout MHC class II proteins, and specific interactions between the peptide and 
the allele specific MHC molecule. Conserved hydrogen bonds with the backbone of 
the peptide confines the peptide conformation.48 Crystal structures and mutation 
studies have shown that these hydrogen bonds are in general contributed by MHC 
class II amino acids α53 (backbone), Asn α62, Asn α69, His β81, and Asn β82 (Figure 
1).49-52 In particular, N-terminal hydrogen bonds strongly influence peptide 
binding.49 
 
Specific binding via hydrogen bonds and hydrophobic interactions occurs through 
binding of peptide amino acid side chains with polymorphic (allele specific) residues 
in MHC pockets. The anchor residues often occupy the P1 (HLA-DR, I-E, DL) and the 
P9 (HLA-DQ, I-A, BL) pocket in the MHC class II molecule, which are the most 
important pockets.53 Less important binding pockets are P4, P6, and P7.54 An MHC 
binding motif is a description of the preferred or observed amino acids at particular 
positions in peptides, binding to the MHC pockets. Alignment of a peptide with the 
motif defines the peptide binding register, i.e., the relative position of the peptide in 
the MHC binding groove. The nomenclature of peptide amino acid residues is 
derived from this register, where the P1 residue is the first (N-terminal) amino acid 
residue that binds to the N-terminal P1 pocket. MHC class I binding motifs are easily 
FIGURE 1. Conserved hydrogen bonds in the I-Ak-HEL peptide complex. 
Shown are the I-Ak MHC class II molecule (ribbon) and HEL51-60 peptide (sticks) from PDB
code 1IAK.50 Putative conserved hydrogen bonds between the peptide and conserved MHC
residues are shown (dashed lines). 
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defined by elution and sequencing of bound peptides, and subsequent alignment is 
facilitated by the restricted length of the peptides.55,56 Due to the high diversity of 
peptide lengths, definition of MHC class II binding motifs is more complicated, and 
besides peptide elution,57,58 phage display,59 positional scanning synthetic 
combinatorial peptide libraries,60 peptide amino acid replacements such as in an 
alanine scan, and truncation studies are used.61 Alignment of a peptide sequence 
with the MHC binding motif, often predicts binding of a certain peptide in one 
possible binding register. By defining this binding mode, it becomes clear which 
peptide amino acid residues are involved in MHC binding, and which amino acids 
are not bound by the MHC and possibly able to contact the TCR (TCR contact 
residues).  
 
 
TCR structure and the MHC-peptide-TCR interaction 
 
TCRs are cell surface heterodimers of which the last years several structures have 
been elucidated by X-ray crystallography (MHC class I restricted isolated TCR 
structures,62-66 MHC class I-peptide-TCR structures33,35,39,67-72 and MHC class II-
peptide-TCR structures).51,73,74 They consist of two disulfide linked chains, the α and 
the β chain. Both chains are folded into two immunoglobulin resembling domains 
each, one variable and one constant domain forming the extracellular structure, 
complemented by a transmembrane domain and a cytoplasmic tail. The two variable 
domains each form three complementarity determining regions (CDRs 1,2,3) and one 
hypervariable loop (HV4). The CDRs 3 exhibit the highest degree of genetic 
variability. 
 
Binding of the TCR to the MHC-peptide complex occurs in a diagonal manner, with 
angles ranging from 45° to 80° (Figure 2). Since only three MHC class II restricted 
TCRs have been crystallized,51,73,74 it is difficult to dissect differences between MHC 
class I and MHC class II restricted TCRs. Nevertheless, it is evident that the peptide 
side chains which are available to contact the TCR are different. While contact 
between a peptide and an MHC class I restricted TCR is focused predominantly on 
the central peptide residues, recognition of peptide side chains by MHC class II 
restricted TCRs is distributed more uniformly. These TCR contact residues are, in 
case of MHC class II bound peptides, P2/P3, P5, and P8, due to the fixed polyproline 
type II twist of the peptide.48 The peptide contributes between 21% and 34% to the 
buried surface area between the TCR and the MHC-peptide complex and forms 
hydrogen bonds, salt bridges, and Van der Waals contacts.38,75  
 
Interaction between MHC-peptide and TCR is dominated by the CDRs 3.38 While the 
CDRs 2 exclusively contact the MHC, CDRs 1 and 3 contact both the MHC and the 
peptide. The CDRs 3 form a cleft in which the central peptide amino acid binds, as a 
‘functional hot spot’.33 Comparison of different crystal structures of TCRs bound to 
MHC-peptide complexes revealed that CDRs 1 and 2 adopt canonical structures, i.e., 
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more or less constant conformations.76 Besides the highest genetic variability, the 
CDRs 3 also show the highest conformational variability. This conformational 
freedom provides the possibility for induced fit, that has shown to appear upon 
binding of an isolated TCR to the MHC-peptide complex.71,77 Recently, a two-step 
model was proposed for engagement of the TCR with the MHC-peptide complex, in 
which CDRs 1 and 2 first guide the TCR-MHC interaction, followed by the CDRs 3 
adjusting to the peptide,78 but the usefulness of this model has already been 
questioned.39 
 
 
Peptide modification and synthesis 
 
Replacement of one amino acid by another amino acid in the peptide, such as in an 
alanine scan, provides a tool for exploring the interactions in the MHC-peptide-TCR 
complex. The influence of modifying a peptide amino acid residue to a residue that 
does not belong to the twenty proteinogenic amino acids, on the interaction with the 
MHC or TCR has also been studied, mainly for two reasons. First, these small and 
large peptide modifications may result from posttranslational modification, that 
include phosphorylation, methylation, deimination/citrullination, deamidation, and 
glycosylation.79 Some of these posttranslational modification processes that can alter 
FIGURE 2. Structure of the MHC class II-peptide-TCR complex. 
Shown are the top part of I-Ak MHC class II molecule (ribbon, bottom), CA134-146 peptide
(sticks), and the V domains of the D10 TCR (ribbon, top) from PDB code 1D9K.51 (A) Side view.
(B) View along the axis of the backbone of the peptide. 
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an epitope, are implicated in (experimental) autoimmune diseases.5,80,81 Second, 
peptides have been modified using peptidomimetic building blocks, solely to study 
the interaction with MHC or TCR, or with the intention to create more active and 
more stable compounds that could possibly be used as therapeutics. An overview of 
posttranslational or peptidomimetic modifications applied to MHC class I and MHC 
class II binding peptides is provided in Tables I and II, respectively. 
 
Table I. Modifications applied to MHC class I binding peptides. 
 
 
Modification 
 
 
References 
 
Glycosylation 
 
82-84 
N- and C-terminal modification 85-87 
(Partial) retro-inverso 88-90 
Linear backbone spacers 91-94 
Cyclic backbone spacer 95 
Poly-N-acetylated amines 96,97 
Reduced amide bond 98-101 
N-alkylation 36 
Oligocarbamates 102 
β-amino acids 103 
N-hydroxy amide 104,105 
Combination of modifications 
 
106 
 
 
Table II. Modifications applied to MHC class II binding peptides. 
 
 
Modification 
 
References 
 
 
Glycosylation 
 
107-113 
Phosphorylation 114 
Deamidation 115 
N- and C-terminal modification 61,116-121 
Retro-inverso 122,123 
Retro-all-peptoid 124 
Pyrollinone-peptide hybrid 125,126 
Aza peptide hybrid 127,128 
α-disubstituted lactam 127 
Reduced amide bond 129-132 
N-methylation 130,131,133,134 
Ethylene moiety 129 
Combination of modifications 61,133-136 
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In this thesis, we have focused on alterations that were inspired by both 
posttranslational modifications, i.e., acetylation, glycosylation, and citrullination, and 
peptidomimetics, exemplified by peptoids. These approaches required the synthesis 
of the building blocks, that subsequently could be incorporated in the peptide amino 
acid sequence, according to normal solid phase peptide synthesis.137 The naturally 
occurring N-linked glycosylated asparagine and non-natural N-linked glycosylated 
glutamine residue were prepared according to a new synthesis method.138 The 
citrulline and ornithine residues that we used, are commercially available. Peptoid 
residues, prepared as Fmoc protected N-substituted glycine building blocks, were 
incorporated in a peptide, creating peptoid-peptide hybrids.139 In peptoid residues 
the side chains are not present on the α-carbon atom of the amino acid backbone but 
on the preceding backbone nitrogen atom instead140 (Figure 3). The side chain 
functionality of a peptoid residue can be chosen as in an amino acid residue. Features 
of peptoid residues include a higher flexibility than amino acid residues.140,141 
Furthermore, peptoids were shown to display an improved stability against 
proteolytic degradation142 as well as in vivo stability,143 favoring their in vivo 
application. 
 
 
Aim and outline of the thesis 
 
The aim of this thesis was to investigate the influence of peptide modifications on the 
interactions in the MHC-peptide-TCR complex in relation to T cell activation. Based 
on crystal structures and a homology model, peptide modifications were designed 
and resulting modified peptides and peptidomimetics were synthesized. 
Immunological experiments were used to evaluate the effects of peptide 
modification, and the immunological outcomes were reconsidered at the molecular 
level. 
 
In Chapter 2, the improvement of the stability of peptide gpMBP72-85 by N-terminal 
acetylation to prevent pyroglutamate formation is described. Furthermore, the 
influence of N-terminal acetylation on MHC binding, T cell activation, and in vivo 
behavior is investigated. We discuss the implications for immunological studies 
FIGURE 3. Structural comparison of an amino acid residue with a peptoid residue. 
In a peptoid residue the side chain is shifted to the backbone amide nitrogen atom from the α-
carbon atom in an amino acid residue.140 
General introduction 
17 
involving this peptide. Chapter 3 presents a molecular model of the MHC class II 
RT1.BL molecule complexed to peptide gpMBP72-85. This model was used to predict 
the TCR contact residues in the peptide. In Chapter 4, we describe the design and 
preparation of peptoid-peptide hybrids, that have shifted side chains at three TCR 
contact residue positions in the peptide. The influence of these modifications on 
MHC binding affinity was tested and studied at the molecular level, by comparing 
the models of an additional set of peptidomimetics with experimentally determined 
MHC binding affinities. In Chapter 5, the influence on T cell recognition of side chain 
shifting, as well as alterations mimicking posttranslational modifications at TCR 
contact residue positions was investigated. The interactions at the interface between 
TCR and MHC-peptide were studied at the molecular level, by examination of the T 
cell proliferative capacity of closely related structures. In Chapter 6, we evaluate the 
in vitro and in vivo behavior of the set of modified peptides, described in the 
previous chapters. In addition, the usefulness and restrictions of structure-based 
design of modified peptides as APLs for immunotherapy in EAE are discussed. 
Finally, in Chapter 7, we summarize data from Chapters 2 through 6, by evaluation 
of the structural and functional aspects of peptide modification. Furthermore, the 
chosen multidisciplinary research strategy to establish these structure-activity 
relationships, is discussed. 
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Abstract 
 
Peptide gpMBP72-85, containing amino acids 72-85 of guinea pig myelin basic 
protein is commonly used to induce experimental autoimmune encephalomyelitis in 
Lewis rats. The N-terminal glutamine in this peptide can cyclize to pyroglutamic 
acid, leading to loss of the first MHC anchor for binding to MHC class II. Acetylation 
of the peptide N-terminus prevents pyroglutamic acid formation and ensures a 
constant quality. An increased MHC binding affinity after N-terminal acetylation 
was observed. This modification also enhanced T cell proliferation of a gpMBP 
reactive T cell clone. The encephalitogenicity of peptide gpMBP72-85 was unaffected 
by acetylation. It is concluded that acetylation improves the chemical stability of 
gpMBP72-85, and is not detrimental but rather favorable for its biochemical and 
immunological, in vitro, and in vivo behavior. 
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Introduction 
 
Peptides are presented to the T cell receptor (TCR) of a T cell by a molecule of the 
major histocompatibility complex (MHC). MHC class II molecules bind peptides, 
derived from extracellular proteins, in an extended polyproline type II twist.1 
Binding affinity is contributed by hydrogen bonds between the peptide backbone 
and conserved residues in the MHC protein, together with specific interactions of 
peptide side chains (MHC anchor residues) in MHC pockets. In MHC class II 
molecules the ends of the peptide binding groove are open, creating the possibility 
for binding of large peptides (reviewed by Madden et al.).2 Elongating the peptide 
with one amino acid residue N-terminal to the first MHC anchor can increase MHC 
class II binding affinity3 and T cell stimulation.4 The observed length heterogeneity of 
MHC class II binding peptides5-7 complicates the definition of peptides that play a 
crucial role in (patho)physiological processes. The presence of a large amount of 
different proteases involved in antigen processing8 and their broad specificity,9,10 
further contributes to the complexity of antigen digestion and peptide formation. 
 
Rat MHC class II RT1.BL molecule binds the amino acid sequence 72-85 in guinea pig 
myelin basic protein (gpMBP72-85).11 The RT1.BL-gpMBP72-85 complex in vitro 
stimulates T cell clone Z1a,12 and in vivo triggers the onset of experimental 
autoimmune encephalomyelitis (EAE), a rodent disease model, mimicking human 
multiple sclerosis.11 The amino acid sequence of peptide gpMBP72-85 starts with a 
glutamine residue. However, it is known that the side chain of an N-terminal 
glutamine or glutamic acid residue can cyclize with the amino terminus of the 
peptide backbone to form pyroglutamic acid. The chemical conversion of an N-
terminal glutamine residue into a pyroglutamic acid residue is catalyzed by both 
base and weak acid. Also, Busby Jr. et al. showed that the enzyme glutamine cyclase, 
present in rat brain and human B lymphocytes, can convert N-terminal glutamine to 
a pyroglutamyl residue.13 Since the cyclization conditions are unknown, as well as to 
what extent it may occur, serious problems may arise in assuring the quality of 
materials with an N-terminal glutamine residue used in experiments in vitro and in 
vivo, and in vaccine preparations.14 
 
In the present report, we show that the N-terminus of peptide gpMBP72-85 cyclizes 
to form pyroglutamic acid, but that N-terminal acetylation stabilizes the peptide, and 
pyroglutamic acid formation is prevented. In addition, N-terminal acetylation 
improved MHC binding capacity as well as T cell proliferation of T cell clone Z1a, 
while EAE severity after immunization in complete Freund’s adjuvant (CFA) was 
unaffected. These data emphasize that the N-terminus of the peptide should be 
carefully chosen. Moreover, N-terminal acetylation ensures an excellent constant 
chemical quality, and likely also an improved stability against proteolysis.15,16 
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Materials and methods 
 
Rats 
Male inbred Lewis rats (6 weeks of age, 200 g), were obtained from Universiteit 
Maastricht (the Netherlands). 
 
Peptide synthesis 
Peptides consisting of amino acid sequence 72-85 of gpMBP (QKSQRSQDENPV) 
were synthesized on an automated peptide synthesizer (model 433A, Applied 
Biosystems) according to general procedures as described before.17 ArgoGel Rink-
NH-Fmoc resin (Argonaut Technologies Inc.) was used for practical reasons, creating 
C-terminal amides. H-WT peptide (indicated with preceding H-, denoting free 
amine; wild type is abbreviated to WT and constitutes the amino acid sequence of 
gpMBP72-85) contained a free N-terminus (Mw=1414 g/mol), while Ac-WT peptide 
was acetylated on the N-terminus (Mw=1456 g/mol), using acetic anhydride capping 
solution. Purification attempts to separate the linear component H-WT from the N-
terminally cyclized pyroglutamyl peptide (here abbreviated to pyroglu peptide) 
were carried out using preparative reversed phase HPLC (Adsorbosphere XL C8, 90 
Å pore size, 10 µm particle size, 22 x 250 mm, Alltech Associates Inc.). Peptide purity 
and identity were checked by analytical reversed phase HPLC (Adsorbosphere XL 
C18, 90 Å pore size, 10 µm particle size, 4.6 x 250 mm, Alltech Associates Inc.) and 
MS analysis (electrospray ionization, Shimadzu QP8000), respectively. 
 
Stability analysis 
Peptides H-WT and Ac-WT were dissolved in water (1 mg/ml) and stored at –20° C, 
20° C (room temperature), and 37° C. Sample content was assessed by MS analysis 
and analytical reversed phase HPLC analysis (C18 column, see above), using UV 
detection at 220 and 254 nm, at a flow rate of 1.0 ml/min and a linear gradient (40 
minutes) from 0.1% trifluoroacetic acid (TFA) in water to 0.085% TFA and 5% water 
in acetonitrile. The retention time of pyroglu peptide was 13.8 min., of H-WT peptide 
14.3 min. (both in the H-WT/pyroglu peptide sample), and of Ac-WT peptide 13.8 
min. Relative amounts of peptides were calculated from integrations of peaks at 220 
nm with the Unipoint™ programme (version 1.65, Gilson®, peak width 0.1, peak 
sensitivity 20). 
 
MHC-peptide binding assay 
The MHC binding capacity of H-WT/pyroglu and Ac-WT peptides was determined 
using a direct MHC-peptide binding assay, as has been described before.18 Briefly, a 
concentration range (0, 8, 16, 32, 64, 128, 256 µM) of competitor peptide (H-
WT/pyroglu or Ac-WT) was incubated together with biotinylated marker peptide 
(gpMBP72-85) and detergent solubilized MHC class II molecules (RT1.BL) for 40 
hours at room temperature and pH 5, in the presence of a protease inhibitor mix. The 
MHC-peptide mixtures were analyzed via non-reducing SDS-PAGE and Western 
blotting. Marker peptide-MHC binding was visualized by enhanced 
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chemoluminescence. The larger the decrease in signal of the marker peptide, the 
higher is the affinity of the competitor peptide (IC50, the concentration of competitor 
resulting in 50% inhibition of binding of the marker peptide). 
 
T cell clone and proliferation assay 
Isolation and maintenance of T cell clone Z1a has been described previously.12 This T 
cell clone was isolated after immunization with gpMBP and maintained by cyclic re-
stimulation with gpMBP. Proliferation was measured in flat bottom 96 wells 
microtiter plates (Costar). Each well contained 2x104 T cells, 1x106 irradiated (3000 
rads) freshly isolated thymocytes as antigen presenting cells (APCs) and a 
concentration range of H-WT/pyroglu or Ac-WT peptide (0.01, 0.1, 1, 10, 25 µg/ml) 
in a total volume of 200 µl Iscove’s modified Dulbecco’s medium (IMDM, 
Invitrogen), supplemented with 2 mM L-glutamine, 50 µM β-mercaptoethanol, 50 
U/ml penicillin, 50 U/ml streptomycin and 2% heat inactivated normal rat serum. 
After 3 days of culturing (37° C, 5% CO2), [3H]-thymidine (0.4 µCi/well, Amersham) 
was added and cells were cultured for another 18-20 hours. Cells were harvested on 
fiberglass filters and [3H]-thymidine incorporation was measured by liquid 
scintillation counting (Wallac Oy). Proliferation is expressed as stimulation index 
(SI), proliferation in presence of antigen divided by background proliferation 
without antigen ± standard deviation (SD) of triplicate samples. 
 
Induction and clinical evaluation of EAE 
EAE was induced by subcutaneous injection of 50 µl of an 1:1 emulsion of an 
aqueous solution of H-WT/pyroglu peptide or Ac-WT peptide (1 mg/ml) and 
complete Freund’s adjuvant (CFA, 4 mg/ml Mycobacterium tuberculosis in oil, 
Difco) in each hind foot pad (in total 50 µg peptide/rat). The weight of the animals 
and clinical signs of EAE were monitored, using a blind protocol, according to a scale 
from 0 to 4: 0, no signs; 0.5, significant weight loss; 1, limp tail; 2, hind leg weakness; 
3, paraplegia; 4, paraplegia with fore limb weakness, moribund condition. 
 
 
Results 
 
N-terminal glutamine in gpMBP72-85 cyclizes to pyroglutamic acid 
The peptide comprising the immunodominant epitope consisting of amino acids 72-
85 of gpMBP (gpMBP72-85) possesses an N-terminal glutamine. It is known that N-
terminal glutamine and, more slowly, glutamic acid residues can cyclize to 
pyroglutamic acid (Figure 1). N-terminal acetylation prevents this cyclization. To 
study the rate of conversion, we assessed by MS and HPLC analysis of the H-
WT/pyroglu peptide sample the purity of H-WT peptide, i.e., gpMBP72-85 with a 
free N-terminus that can cyclize to pyroglutamic acid, and also Ac-WT, i.e., N-
terminally acetylated gpMBP72-85. At the start of this study, the H-WT/pyroglu 
peptide sample contained approximately 80% linear peptide (H-WT) and 19% 
pyroglu peptide (Figure 2); in contrast, in the Ac-WT peptide sample (93% pure) no 
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pyroglutamate containing peptide was present. Figure 2 shows that, when the 
samples were stored at –20º C, the composition of both the H-WT/pyroglu peptide 
and Ac-WT peptide samples remained unchanged for the duration of the study (four 
weeks). At higher temperatures (room temperature and 37º C), mimicking conditions 
of biochemical, in vitro, and in vivo studies, the quality of the H-WT/pyroglu 
peptide sample deteriorated quickly (T½,37º C approximately 13 days). Almost all 
disappeared H-WT peptide was converted to the pyroglu peptide (data not shown). 
Only the large decrease in amount of H-WT peptide at 20º C at day 28 seemed to be 
the result of the formation of an unknown product. Ac-WT peptide was stable under 
all circumstances, including acidic conditions of 0.1% trifluoroacetic acid or 5% acetic 
acid (data not shown). 
 
FIGURE 1. Pyroglutamic acid formation by the N-terminal glutamine residue in H-WT peptide, 
and prevention of cyclization by an N-terminal acetyl group in Ac-WT peptide. 
FIGURE 2. Stability of H-WT and Ac-WT peptides in water. 
Amounts of H-WT (A) and Ac-WT (B) peptides were measured by HPLC analysis at different
time points during four weeks. Samples were stored at –20º C, 20º C (room temperature), and
37º C. 
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N-terminal acetylation improves MHC binding capacity and T cell stimulation 
Peptide binding to MHC class II molecules occurs partly through interaction of 
peptide amino acid side chains of MHC anchor residues in pockets formed by the 
MHC molecule. The amino acid side chain of the N-terminal glutamine in peptide 
gpMBP72-85 occupies pocket 1 in MHC class II molecule RT1.BL (Chapter 3).19,20 
Cyclization of this amino acid would therefore result in the loss of an MHC anchor. 
Indeed we showed a reduced MHC binding affinity of the H-WT/pyroglu peptide 
sample compared to the Ac-WT peptide sample (Figure 3). N-terminal acetylation of 
gpMBP72-85 also improved proliferation of T cell clone Z1a (Figure 4).12 The 
proliferative response caused by the H-WT/pyroglu peptides could reach the same 
maximum proliferation as caused by Ac-WT, pointing to a qualitatively similar 
response. 
 
N-terminal acetylation does not influence encephalitogenicity 
Peptide gpMBP72-85 is used regularly for induction of EAE in Lewis rats. After 
noticing the enhanced MHC binding affinity and T cell stimulatory capacity after N-
terminal acetylation of gpMBP72-85, we investigated the encephalitogenic properties 
of the H-WT/pyroglu peptide mixture and the Ac-WT peptide. Table I shows a 
comparison between H-WT/pyroglu peptide and Ac-WT induced EAE. All animals 
displayed a comparable disease development, and no significant differences in 
severity were found. Ex vivo analysis of T cells of the draining lymph nodes from Ac-
WT immunized animals revealed that these cells recognized both H-WT/pyroglu 
and Ac-WT peptides (data not shown). 
 
FIGURE 3. MHC binding of H-WT/pyroglu and Ac-WT peptides. 
(A) Relative MHC binding capacity was measured by means of a competition assay, using
isolated MHC class II molecules, marker peptide, and a concentration range (0-256 µM) of H-
WT/pyroglu or Ac-WT peptide. (B) The crossing between the dashed line and the curve
indicates the IC50 value, the concentration of competitor resulting in 50% inhibition of MHC
binding of the marker peptide. 
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Table I. EAE induction with H-WT/pyroglu peptide and Ac-WT peptide.a 
 
 
Compound 
 
EAE development 
 
  
Incidence 
 
Maximum severityb 
 
 
H-WT/pyroglu 
 
5/5c 
 
2.0 ± 0.4d 
Ac-WT 5/5c 1.7 ± 0.4d 
 
 
 
 
FIGURE 4. Proliferative response of T cell clone Z1a. 
Proliferative responses of T cell clone Z1a generated using the gpMBP protein, were tested
using a concentration range of H-WT/pyroglu peptide or Ac-WT peptide. Proliferation is
expressed as SI ± SD of triplicate samples. Data are from a representative experiment (n=2). 
aEAE was induced by subcutaneous injection in the hind foot pads of male
Lewis rats (200 g) with an 1:1 emulsion of an aqueous solution containing 
50 µg peptide and CFA. 
bMean maximum score of all animals ± SEM, scale 0-4. 
cNumber of animals with EAE / number of animals tested. 
dNot significantly different as determined by Student’s t-test (p = 0.6). 
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Discussion 
 
In the present paper we show that the N-terminal glutamine in peptide gpMBP72-85 
cyclizes to a pyroglutamyl residue, and that N-terminal acetylation stabilizes the 
peptide by preventing this cyclization. Interestingly, other groups have shown that 
N-terminal acetylation of MHC binding peptides, which contain N-terminal amino 
acid residues that cannot undergo cyclization, decreased the proteolytic 
degradation15,16 and improved their stability in human plasma.21 We demonstrated 
that acetylation improved MHC binding. It is possible that part of the improved 
binding capacity of the acetylated peptide results from additional interactions with 
the acetyl group, in addition to the availability of the glutamine side chain for MHC 
binding. It was shown that elongation of MHC class II bound peptides either by 
acetylation15,22 or by attachment of an additional amino acid residue3 can also result 
in higher MHC binding capacity, depending on the position of the peptide N-
terminus in the MHC binding groove.22 From studies of the crystal structure of the 
MHC class II molecule I-Au with peptide MBP1-11, He et al. concluded that N-
terminal acetylation of this peptide is necessary for MHC binding.23 
 
Besides MHC binding capacity, acetylation of gpMBP72-85 also improved the 
stimulation of T cell clone Z1a, generated using the gpMBP protein. This can be due 
to the higher MHC binding capacity of the Ac-WT peptide, leading to more MHC-
peptide complexes than that are formed using the H-WT/pyroglu peptide mixture. 
Additionally, it could be possible that the MHC-Ac-WT peptide complexes might 
induce stronger T cell proliferation than the MHC-peptide complexes formed with 
the H-WT/pyroglu peptides, although the H-WT/pyroglu peptides could reach the 
same maximum proliferation at higher concentrations. Our data indicate that despite 
this improved in vitro behavior after N-terminal acetylation of gpMBP72-85, the 
encephalitogenicity was not enhanced. Also Maillère et al. showed no benefit from 
acetylation of an MHC class II restricted T cell epitope on in vivo priming of T cells, 
despite better MHC binding and T cell proliferative capacity.22 One explanation for 
the absence of improved in vivo behavior after N-terminal acetylation, could be the 
fact that EAE was induced by injection of a water/oil emulsion, which could affect 
the formation of pyroglutamic acid. However, it has been shown that pyroglutamic 
acid formation (in an N-terminal glutamic acid containing peptide) can also occur in 
a water-in-oil formulation.24 Therefore, other factors that determine the severity of 
EAE are more likely to be important. It could well be possible that the lower 
availability of the linear H-WT peptide in the animals injected with the H-
WT/pyroglu peptide mixture does not decrease disease incidence and severity, 
because the administered dose is close to the dose inducing EAE with maximal 
severity. This is consistent with observations that large dose ranges of gpMBP72-85 
peptide emulsified in CFA can induce EAE with comparable severity.25-28 This lack of 
relationship between peptide dose and EAE severity, might be because gpMBP72-85 
immunization only serves as a trigger for the autoimmune reaction against rat MBP, 
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and possibly the Ac-WT peptide does not resemble the naturally processed self 
peptide from rat MBP more closely than the H-WT or the pyroglu peptides. 
 
It is still unknown which amino acids constitute the N-terminus of the 
immunodominant in vivo released self peptide from rat MBP. A large number of 
proteases involved in antigen processing has been described,8 but this list is probably 
not complete.9,29 Furthermore, the data collected on protease activity in vitro are 
difficult to extrapolate to events in vivo.10,29,30 The self peptide that is naturally 
processed from rat MBP may contain a number of amino acids N-terminally 
positioned with respect to Gln72, which can prevent formation of the pyroglutamyl 
N-terminus. In human MBP cleavage between amino acid 68 and 69 using lysosomal 
extracts has been demonstrated,31 but further exoprotease trimming (reviewed in 
references 9, 10, 29, and 30) was expected, possibly exposing Gln72. Importantly, the 
release of the self MBP peptide comprising the N-terminal pyroglutamyl residue has 
been confirmed in preparations of human MBP isolated from myelin membranes, 
containing a metalloprotease that cleaves MBP between the Pro71 and Gln72, 
revealing the N-terminal glutamine.32 Metalloproteases are present in the brain,33 and 
it was hypothesized that in pathological conditions, these enzymes could play a role 
in demyelination.32 Instead of cyclizing, the released N-terminal glutamine might be 
acetylated in vivo as a result of posttranslational modification processes.34 N-
terminal acetylation is required for T cell recognition of epitope MBP1-11 in the 
mouse model of EAE.35 The presence of acetyl groups and also larger acyl groups on 
the protein N-terminus in human MBP has been documented.36 To our knowledge, 
no observations have been published on the natural occurrence of an N-terminal 
acetyl group in gpMBP72-85 or rat MBP72-85. 
 
In the past, research has been focused on defining the amino acid sequence of the 
epitope recognized by encephalitogenic T cells in EAE and less effort has been 
directed to identify the actually in vivo released and recognized self peptide. 
Although it is unknown whether N-terminal acetylation mimics the biological 
situation, we show in this report that there are distinct advantages for using 
acetylated gpMBP72-85. The MHC binding as well as the induction of T cell 
proliferation improves due to acetylation, while the encephalitogenicity remains 
unaffected. Furthermore, we provide evidence that the chemical quality of the 
unacetylated peptide is difficult to control, and that acetylation stabilizes the peptide. 
Therefore, it should be emphasized that the choice for the chemical nature of the 
peptide N-terminus must be carefully made. 
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Abstract 
 
Structural information regarding binding of peptides to the major histocompatibility 
complex (MHC) class II molecule is of great use for the design of compounds that 
intervene in the interaction between the MHC-peptide-T cell receptor (TCR) 
complex. These compounds can be applied in the treatment of T cell mediated 
autoimmune disease for specific modulation of the disease process. In case no crystal 
structure of the MHC molecule is available, homology models of the MHC molecule 
can be of importance. Here we describe the construction of a homology model of the 
MHC class II molecule and binding of the peptide, that are involved in experimental 
autoimmune encephalomyelitis, a rat model for human multiple sclerosis. The 
validity of the model was investigated using experimental data of peptides binding 
to this MHC molecule. 
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Introduction 
 
Major histocompatibility complex (MHC) class II proteins bind peptides in an 
extended polyproline type II twist,1 due to a number of conserved hydrogen bonds.2 
The T cell receptor (TCR) interacts with these specific MHC-peptide complexes and 
when the MHC-peptide complex is recognized this can lead to activation of the T 
cell. Blocking the interaction between the MHC and the peptide has been shown to 
inhibit T cell activation specifically.3 Furthermore, altered peptide ligands (APLs) are 
exploited for application in autoimmune disease. MHC presented APLs have a 
changed interaction with the TCR, which leads to an altered T cell response that can 
modulate the disease.4 For these peptides, structural information regarding the mode 
of binding of the peptide to the MHC is of great importance. Here, the construction 
of a homology model of the MHC class II RT1.BL molecule is reported, and binding 
of peptide sequence 72-85 of guinea pig myelin basic protein sequence (gpMBP72-
85)5 is investigated. 
 
 
Materials and methods 
 
Molecular modeling 
The sequence of the RT1.BL α chain was based on TrEMBL6 entry Q95572, with a few 
differences: Q108P, LVE148-150WLR, F183S (Broeren, C. P. M., et al., personal 
communication). The sequence of the RT1.BL β chain was downloaded from SWISS-
PROT,6 accession number P29826. BLAST searches7 in the Protein Data Bank (PDB)8 
for both the α and β chain showed highest sequence similarity with I-Ak (79% and 
84%, respectively). According to a multiple alignment (ClustalW)9, the three-
dimensional structure of RT1.BL was built from PDB entry 1IAK,10 using the WHAT 
IF Web Interface (release July 2000 at the CMBI, the Netherlands).11,12 Peptide 
gpMBP72-85 was modeled by replacing the amino acid residues of the HEL peptide 
in the I-Ak crystal structure by alanine residues. Fragments proposed by the 
programme LUDI13 were used to define a peptide binding motif of RT1.BL. Using this 
motif, gpMBP72-85 was manually docked into the groove by changing the alanine 
residues into the appropriate amino acid residues (QKSQRSQDENPV). 
 
Synthesis of peptides 
Peptides (N-acetylated, C-amidated) (Chapter 2)14 were synthesized by automated 
simultaneous multiple peptide synthesis (SMPS).15 Purity and identity were checked 
by reversed phase HPLC (C18) and MS analysis.  
 
MHC binding assay 
The MHC binding capacity of the compounds was determined using a direct MHC-
peptide binding assay, as described.16 Briefly, a concentration range (0-256 µM) of 
competitor peptide was incubated together with biotinylated marker peptide 
(gpMBP72-85) and detergent solubilized RT1.BL molecules for 40 hours at room 
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temperature and pH 5, in the presence of a protease inhibitor mix. The MHC-peptide 
mixtures were analyzed by non-reducing SDS-PAGE followed by Western blotting. 
Binding of the marker peptide was detected by enhanced chemoluminescence. The 
affinity is expressed as IC50, the concentration of competitor peptide resulting in 50% 
inhibition of binding of the marker peptide. 
 
 
Results and discussion 
 
Molecular modeling 
For the design of MHC class II binding peptides, a homology model of RT1.BL 
complexed with peptide gpMBP72-85 was constructed, since no crystal structure of 
this MHC molecule was available. The three-dimensional structure of RT1.BL 
including the peptide consisting of alanine residues, was built from PDB entry 
1IAK.10 A peptide binding motif was then generated using the programme LUDI.13 
The fragments proposed at the different positions in the alanine peptide (P-2, P-1, P1, 
P2…P11, according to the amino acid numbering of the HEL peptide in I-Ak) to fit 
the MHC binding pockets, were interpreted as amino acids (Table I, upper panel). A 
fully flexible docking simulation of a peptide of this length can not be performed.17 
Therefore, the gpMBP72-85 peptide was aligned with the motif and the most 
probable docking registers of the peptide (Table I, lower panel) were scored as 
follows: identities (the amino acid is identical to an amino acid in the motif at that 
position) with score 1, strong preference identities (in case of strong preference for 
that amino acid in the motif) with score 2, and positives (the amino acid resembles an 
amino acid in the motif at that position) with score 0.5. Alignment of the peptide 
with glutamine 72 as P1 (Gln1) and glutamic acid 82 as P9 (Glu9) resulted in the 
highest total score (sum of scores of all amino acids in the peptide) of 8.5. Docking of 
the peptide was validated using experimental MHC-peptide binding data of the 
gpMBP72-85 peptide and other RT1.BL binding peptides.18 According to these 
experiments, the peptide positioning in the groove was the same as proposed above. 
 
MHC binding 
We established that relative position 1 (P1), P7, and P9 were MHC anchors. The 
MHC-peptide model showed three amino acid residues in the peptide pointing 
upwards to the TCR (TCR contact residues): the lysine at relative position 2 (Lys2), 
Arg5 and Asp8 (Figure 1). Modifications to these three amino acid residues were 
expected to change the interaction with the TCR, what could result in the desired 
APL function. To investigate which type of replacements could be made without 
affecting the MHC binding affinity, alanine and glycine substitutions at these three 
positions were made. The structures of the peptides are shown in Table II. WT is 
peptide gpMBP72-85, and for example in peptide Lys2Ala, Lys2 was replaced by 
alanine. All alanine and glycine substituted peptides showed high MHC binding 
affinity (Table II). Thus, the side chains of those residues did not have important 
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Table I. MHC binding motif and peptide docking. 
 
    
Relative position 
 
     
    
–2 
 
–1 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
11 
 
     
 
                     
c L Q Y L S R N R F Q R Y      Binding 
motifa  P E N K K Y H W L E Y Q      
     N H P Q Q  Y  H K       
     H K F  H  H          
      F   W  Q          
                     
   Q K S Q R S Q D E N P V  6.5 
  Q K S Q R S Q D E N P V  5  
Peptide 
docking and 
scoreb  Q K S Q R S Q D E N P V  8.5   
    Q K S Q R S Q D E N P V  3.5    
   Q K S Q R S Q D E N P V  4.5     
  Q K S Q R S Q D E N P V  5.5      
 Q K S Q R S Q D E N P V  4       
Q K S Q R S Q D E N P V  2.5        
                     
 
interactions with the MHC molecule. At the same time, these results indicated that 
the proposed docking of the peptide (Figure 1) might be correct. 
 
 
Conclusions 
 
With the homology modeling procedure and our docking method described, we 
were able to produce a useful model of the MHC class II-peptide complex. The 
amino acid residues that were predicted to point out of the MHC binding groove 
could be replaced by alanine and by glycine residues. This indicated that the side 
chains of these amino acid residues were not involved in interaction with the MHC. 
This knowledge can now be expanded to the rational design of altered peptide 
Relative position refers to amino acid numbering of the HEL peptide in I-Ak.10 
aUpper panel: all preferred amino acid residues (one letter code) at one position are printed
beneath each other. Italic font indicates a strong preference. Amino acid residues aligned
horizontally are not related to each other. 
bLower panel: possible peptide docking registers and scores. Bold print indicates identities
(score 1), italic font points to strong preference (score 2), and positives are underlined (score
0.5). Score shown is the sum of scores of all amino acids in the peptide. 
cAt this position no preference was found. 
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ligands, in which these three amino acids are replaced by other amino acids or non-
peptide building blocks. 
 
 
Table II. Structures and binding affinities of peptides. 
 
 
Compound 
  
Structure 
 
 
MHC affinity 
IC50 (µM)a 
   
P2 
 
P5 
 
P8 
 
 
 
      
WT  Lys Arg Asp ≤ 8 
Lys2Ala  Ala Arg Asp ≤ 8 
Arg5Ala  Lys Ala Asp ≤ 8 
Asp8Ala  Lys Arg Ala ≤ 8 
Lys2Gly  Gly Arg Asp ≤ 8 
Arg5Gly  Lys Gly Asp ≤ 8 
Asp8Gly  Lys Arg Gly ≤ 8 
      
 
 aRelative binding affinity of the competitor is expressed as IC50, the 
concentration of competitor resulting in 50% inhibition of MHC
binding of the marker peptide. 
FIGURE 1. Schematic side view of the RT1.BL-gpMBP72-85 model. 
Shown is the top part of the MHC (ribbon) and the peptide (only polar hydrogen atoms are
shown). 
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Abstract 
 
The major histocompatibility complex (MHC) class II binding requirements for 
solvent-exposed peptide residues were systematically studied using amino acid and 
peptoid substitutions. In a peptoid residue the side chain is present on the backbone 
nitrogen atom as opposed to the α-carbon atom in an amino acid residue. To 
investigate the effect of this side chain shifting on MHC binding, three amino acid 
residues in the central part of the peptide sticking out of the binding groove were 
replaced by corresponding peptoid residues. Two peptoid-peptide hybrids showed 
large affinity decreases in the MHC-peptide binding assay. To investigate this 
affinity loss, the individual contributions to MHC binding affinity of the side chain 
(position), the putative hydrogen bond, and the flexibility were dissected. We 
conclude that the side chain position as well as the backbone nitrogen atom 
hydrogen bonding features of solvent-exposed residues in the peptide can be 
important for MHC binding affinity. 
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Introduction 
 
Major histocompatibility complex (MHC) class II proteins are cell surface 
glycoproteins that are present on professional antigen presenting cells. They bind 
peptides derived from merely extracellular proteins in an extended polyproline type 
II twist,1 which is held by several conserved hydrogen bonds.2,3 Such specific MHC-
peptide complexes are recognized by CD4+ T cells via the T cell receptor and 
subsequent signaling results in activation of the T cell. In peptidomimetic 
compounds, amino acid residues are replaced by non-peptidic building blocks. 
Several reports have been published investigating MHC class I (e.g., references 4 and 
5) and MHC class II binding of certain types of peptidomimetics. These modifications 
can be divided into backbone modifications on the one hand, involving N-
methylation,6-8 amide bond reduction,8,9 replacement of the amide bond by an 
ethylene bond9 or a cyclic moiety,6,8,10-12 and side chain modification on the other 
hand, introducing unnatural amino acid residues.6,7,13 
 
Here, we describe the design, synthesis, and MHC class II binding characteristics of 
peptoid-peptide hybrid peptidomimetics. The synthesized hybrids consist of amino 
acid residues, in which only one amino acid residue is replaced by the corresponding 
peptoid residue. In peptoid residues the position of the side chain is shifted from the 
α-carbon atom to the nitrogen atom.14 The identity of the side chain is conserved, 
while the direction in three-dimensional space is changed. These compounds may be 
considered a combination of backbone and side chain modifications. Using stepwise 
replacement of three solvent-exposed amino acid residues for a peptoid residue, and 
an additional set of compounds, the structural features of peptoid-peptide hybrids 
were thoroughly investigated. 
 
The MHC class II molecule RT1.BL and peptide sequence 72-85 of guinea pig myelin 
basic protein (gpMBP) we studied, play a major role in the rat experimental 
autoimmune encephalomyelitis model (EAE, resembling human multiple sclerosis).15 
Starting from this peptide, peptoid-peptide hybrids were designed to investigate the 
influence on MHC binding of side chain shifting at solvent-exposed sites in the 
central part of the peptide. 
 
 
Materials and methods 
 
Synthesis of peptides and peptoid-peptide hybrids 
Peptoid monomers NLys (peptoid residue corresponding to Lys), NArg, and NAsp 
were synthesized according to general procedures as described earlier.16 Peptide WT 
(gpMBP72-85, sequence QKSQRSQDENPV) was synthesized on an automated 
peptide synthesizer (model 433A, Applied Biosystems), as described previously.16 
ArgoGel Rink-NH-Fmoc resin (Argonaut Technologies Inc.) was used to obtain C-
terminal amides. The N-terminus of the peptide was acetylated with acetic 
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anhydride capping solution (Chapter 2).17 The peptoid-peptide hybrids were 
synthesized analogously, with minor variations: coupling of the peptoid monomer to 
the preceding amino acid was carried out with O-(7-azabenzotriazol-1-yl)-N,N,N',N'-
tetramethyluronium hexafluorophosphate (HATU) and 1-hydroxy-7-
azabenzotriazole (HOAt) instead of O-benzotriazole-1-yl-N,N,N',N'-
tetramethyluronium hexafluorophosphate (HBTU) and 1-hydroxybenzotriazole 
(HOBt). Subsequent coupling of the next amino acid to the peptoid monomer was 
performed as a double coupling, also using HATU/HOAt, after which a capping 
step was introduced. The peptides with alanine and glycine substitutions (Chapter 
3)18 were synthesized by automated simultaneous multiple peptide synthesis 
(SMPS).19 The peptides and hybrids were purified by reversed phase HPLC (C18) 
when necessary, and checked by MS analysis.  
 
MHC-peptide binding assay 
The MHC binding capacity of the compounds was determined using a direct MHC-
peptide binding assay, as has been described before.20 Briefly, a concentration range 
(0-256 µM) of competitor (peptide or hybrid) was incubated together with 
biotinylated marker peptide (gpMBP72-85) and detergent solubilized MHC class II 
molecules (RT1.BL) for 40 hours at room temperature and pH 5, in the presence of a 
protease inhibitor mix. Non-reducing SDS-PAGE and Western blotting were used for 
analysis of the MHC-peptide mixtures. Marker peptide-MHC binding was visualized 
by enhanced chemoluminescence. The larger the decrease of signal of the marker 
peptide, the higher the affinity of the competitor peptide (expressed as IC50, 
concentration of competitor resulting in 50% inhibition of binding of the marker 
peptide). 
 
 
Results and discussion 
 
Design and synthesis of peptoid-peptide hybrids 
For investigation of peptide-MHC class II binding requirements, a homology model 
of RT1.BL complexed with peptide gpMBP72-85 was used (Chapter 3),18 since no 
crystal structure of this MHC molecule was available. The MHC-peptide model 
showed three amino acid residues in the peptide sticking out of the MHC binding 
groove: the lysine at relative position 2 (Lys2), Arg5, and Asp8 (Figure 1). 
Replacements of these three amino acid residues into alanine and glycine (one at a 
time) did not reduce MHC binding affinity (Table I and Chapter 3),18 indicating that 
the side chains of these three amino acid residues were not involved in MHC 
binding. The same three amino acid residues were changed into their corresponding 
peptoid residues (NLys, NArg, and NAsp, respectively), to investigate whether it 
was possible to shift solvent-exposed side chains, that are within the peptide binding 
core. The structures of the peptides and hybrids are shown in Figure 2 and Table I. 
WT is the acetylated and amidated gpMBP72-85 peptide, and for example in hybrid 
Lys2NLys, Lys2 was replaced by the corresponding peptoid residue NLys. 
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MHC binding affinity of peptoid-peptide hybrids 
In the concentration range tested, no MHC binding could be detected for two of the 
three hybrids with shifted side chains (Lys2NLys and Arg5NArg, Table I), while 
Asp8NAsp displayed only a small affinity decrease (IC50 = 16-32 µM) compared to 
the WT peptide (IC50 ≤ 8 µM). To investigate the differences between a peptoid and 
an amino acid residue systematically, we tried to dissect the overall change resulting 
from the modification of an amino acid to a peptoid residue into individual 
components. Therefore, the following consequences of the introduction of a peptoid 
residue were investigated, and possible reasons for the affinity loss were 
hypothesized: 
Altered position of the side chain: 
1a. The side chain of the amino acid residue is required at its original position. 
1b. The side chain of the peptoid residue is in an unfavorable location. 
Increased flexibility: 
2. Increased loss of entropy occurs upon binding of the peptoid-peptide 
hybrid to the MHC. 
Alkylation of the backbone nitrogen atom: 
3. Potential hydrogen bond cannot be formed. 
These effects were studied using sets of Ala (no functional side chain) and Gly 
(flexible) substituted peptides, and NAla (no NH) substituted peptoid-peptide 
hybrids (Table I). MHC binding results of these compounds together with the flow 
charts shown in Figure 3, made it possible to confirm or reject the above described 
hypotheses. 
 
Side chain binding of amino acid residues 
The contribution of the amino acid side chains at the three positions to the binding 
affinity (Hypothesis 1a) was studied by comparing the binding affinity of the WT 
peptide with that of the alanine substituted analogues. These peptides all showed 
high binding affinity (Table I), which indicated that the side chain of the changed 
amino acid residue was not necessary for MHC binding. Hypothesis 1a was therefore 
rejected. 
FIGURE 1. Schematic representation of the RT1.BL-MBP72-85 model. 
Shown is the top part of the MHC (ribbon) and the peptide (only polar hydrogen atoms are
shown) with Lys2, Arg5, and Asp8 projecting out of the MHC binding groove. 
Chapter 4 
56 
 
Table I. Structures and binding affinities of peptides and hybrids. 
 
 
Structure 
  
MHC binding affinity 
 
 
Compound 
 
 
P2 
 
P5 
 
P8 
  
Concentration of competitor (µM) 
 0 8 16 32 64 128 256a 
 
 
IC50 
(µM)b 
 
 
WT 
 
 
 
 
Lys 
 
 
Arg 
 
 
Asp 
  
 
 
 
≤ 8 
 
Lys2Ala 
 
 
 
 
Ala 
 
Arg 
 
Asp  
 
 
≤ 8 
 
Arg5Ala 
 
 
 
Lys 
 
Ala 
 
Asp  
 
 
≤ 8 
 
Asp8Ala 
 
 
 
Lys 
 
Arg 
 
Ala  
 
 
≤ 8 
 
Lys2Gly 
 
 
 
 
Gly 
 
Arg 
 
Asp  
 
 
≤ 8 
 
Arg5Gly 
 
 
 
Lys 
 
Gly 
 
Asp 
 
 
 
≤ 8 
 
Asp8Gly 
 
 
 
Lys 
 
Arg 
 
Gly 
 
 
 
≤ 8 
 
Lys2NLys 
 
 
 
NLys 
 
Arg 
 
Asp 
 
 
 
≥ 227 
 
Arg5NArg 
 
 
 
Lys 
 
NArg 
 
Asp 
 
 
 
≥ 256 
 
Asp8NAsp 
 
 
 
Lys 
 
Arg 
 
NAsp 
 
 
 
16 - 32 
 
Lys2NAla 
 
 
 
NAla 
 
Arg 
 
Asp 
 
 
 
64 - 128 
 
Arg5NAla 
 
 
 
Lys 
 
NAla 
 
Asp 
 
 
 
64 - 256 
 
Asp8NAla 
 
Lys 
 
Arg 
 
NAla 
 
 
 
 
≤ 8 
 
aInhibition of binding of biotinylated marker peptide to isolated RT1.BL molecules is 
shown in a dose range from 0 to 256 µM competitor peptide/hybrid. 
bRelative binding affinity of the competitor is expressed as IC50, the concentration of 
competitor resulting in 50% inhibition of MHC binding of the marker peptide. 
 
MHC class II binding of peptoid-peptide hybrids 
57 
Influence of flexibility 
The flexibility of the peptoid-peptide hybrid was expected to be larger than that of a 
peptide, since a peptoid residue can adopt more conformations than an amino acid 
residue.14,21 To investigate whether increased flexibility and therefore increased loss 
of entropy upon binding to the MHC molecule affected the affinity (Hypothesis 2), 
glycine substituted peptides were examined (Table I). When compared to the alanine 
FIGURE 2. Structures of peptide WT and peptoid-peptide hybrids Lys2NLys, Arg5NArg, and
Asp8NAsp, with amino acid residues at positions 2, 5, and 8, respectively, replaced by
corresponding peptoid residues. 
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substituted peptides, the flexibility of those glycine substituted peptides has 
increased. As these glycine substituted peptides all showed high MHC binding 
affinity, we concluded that the expected increased flexibility of the peptoid-peptide 
hybrids, was not deleterious to MHC binding. 
 
Hydrogen bonding features 
In the next step in the flow charts (Figure 3) the contribution of a putative hydrogen 
bond between the backbone nitrogen atom in the peptide and the MHC molecule 
(Hypothesis 3) was evaluated. After replacement by a peptoid residue no hydrogen 
bond involving the NH was possible. It has been shown that disruption of one 
hydrogen bond between the peptide backbone and the MHC can result in a decrease 
in binding affinity.8,22 On the other hand, the contribution of hydrogen bonds to 
affinity is often overrated, especially at solvent-exposed positions.23 The importance 
of the disappearance of the hydrogen bond donor was tested in peptoid-peptide 
hybrids with NAla (N-methyl glycine) inserted. Taking the step from a glycine 
substituted peptide to an NAla peptoid-peptide hybrid, the main difference was the 
disappearance of the hydrogen atom from the backbone nitrogen atom (Figure 3). At 
position 2, methylation of the backbone nitrogen atom (compare Lys2NAla to 
Lys2Gly, Figure 3A) resulted in a large loss of affinity, which may point to the 
required presence of a hydrogen bond at that site. The same occurred at position 5 
(Figure 3B). At position 8 no reduction in binding affinity was detected. Apparently, 
no such hydrogen bond was present in the peptide at that position. The hydrogen 
bond between the backbone nitrogen atom at position 2 in the peptide and the MHC 
(Asnβ82) has been described in the literature as a conserved hydrogen bond.2,3 
Recently, McFarland et al. reported that this hydrogen bond contributes significantly 
to MHC binding affinity.24 At positions 5 and 8, no conserved hydrogen bonds are 
known. 
 
Side chain binding of peptoid residues 
From the model of the peptide-MHC complex (Figure 1), it could be deduced that the 
direction of the peptoid side chain in three-dimensional space could have been 
changed (about -30 degrees), compared to the amino acid side chain. This is due to 
the polyproline type II twist, which is a general feature of MHC class II bound 
peptides.1 The change in direction may have resulted in forcing the (charged) 
functional group of the side chain of the peptoid residue into an unfavorable position 
(Hypothesis 1b). The modification may also have caused dislocation of one of the 
adjacent MHC anchor residues, due to a distorted backbone.11 In the last step in the 
flow charts, it was evaluated if the side chain on the backbone nitrogen atom could 
be elongated from NAla to the peptoid residue corresponding to the original amino 
acid residue at that position. At all three positions a small (additional) affinity 
decrease was observed, indicating the position of the peptoid side chain was 
unfavorable. 
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FIGURE 3. Flow charts describing the structural changes resulting from the replacement of an
amino acid residue by a peptoid residue. 
Shown are parts of structures and their contributions to binding affinities (left: high affinity;
right: low affinity) of compounds altered at position 2 (A), position 5 (B), and position 8 (C). 
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Conclusions 
 
It is intriguing that shifting the side chain from the Cα to the N atom at originally 
solvent-exposed peptide residues, had such an effect on MHC binding. Howard et al. 
have reported a retropeptoid mimicking a high affinity binder.25 No MHC binding 
could be detected for the retropeptoid, in which all amino acid residues were 
replaced by peptoid residues (in reversed order). A retropeptoid is expected to bind 
in opposite direction in the MHC binding groove as compared to a peptide or 
peptoid-peptide hybrid with one peptoid residue. As a result, the side chains of the 
peptoid residues can point in the same direction as the side chains in the original 
peptide, assuming that the backbone carbonyl groups reside in their original 
positions in the MHC. Therefore, the lack of MHC binding in this case may be 
attributed to the loss of all backbone hydrogen bond donors, or to the increased 
flexibility. 
 
In this study, we investigated the differences between a peptoid residue and an 
amino acid residue at a solvent-exposed site in the peptide, in relation to MHC class 
II binding affinity. With the strategy that was described here, the contribution of the 
side chain, backbone, and overall structure to MHC binding were separated. We 
realize, however, that by adopting the above described deduction strategy, 
synergistic and counteractive effects of the separate contributions were not taken into 
account. It was shown that the side chains of the three selected solvent-exposed 
amino acid residues were not involved in MHC binding, whereas the side chains of 
the peptoid residues were in unfavorable locations. Presumably increased flexibility 
of the peptoid-peptide hybrids did not hamper MHC binding. A large affinity loss 
was seen when amino acid residues at positions 2 or 5 were altered into their 
corresponding peptoid residues, and this could be mainly attributed to the loss of a 
putative hydrogen bond of the backbone nitrogen atom with the MHC. Apparently, 
no such hydrogen bond was formed at position 8. In conclusion, these results 
indicate that the side chain position, as well as the backbone nitrogen atom hydrogen 
bonding features of solvent-exposed residues of the peptide could be important for 
MHC binding. 
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Abstract 
 
The balance between specific and degenerate T cell recognition of MHC class II 
bound peptides is crucial for T cell repertoire selection, and holds important 
implications for protective immunity versus autoimmunity. To investigate the degree 
of degeneracy in T cell recognition, we applied selected modifications to T cell 
receptor (TCR) contact residue amino acids in the MHC class II bound epitope 
gpMBP72-85. By using glycosylated amino acids, as an example of a posttranslational 
modification, large alterations were applied. Small modifications were accomplished 
by exchanging an arginine residue for a citrulline or an ornithine residue. Finally, the 
unmodified TCR contact residue side chains were shifted one atom position to the 
left, using peptoid residues. Both these large and subtle changes in the wild type 
(WT) peptide caused lack of recognition by WT peptide specific monoclonal and 
polyclonal T cells. Furthermore, T cells specific for the modified peptides did not 
crossrecognize the WT peptide. Using a set of additional compounds, we 
investigated the specificity of these T cell populations into detail. Our data reveal a 
strongly limited plasticity in T cell recognition, and a high specificity for TCR contact 
residue side chains. 
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Introduction 
 
In fulfilling their protective task, T cells must recognize MHC-non-self peptide 
complexes which differ from the MHC-self peptide complexes to which they were 
positively selected in the thymus.1 This degenerate recognition is the result of 
plasticity in T cell recognition, and is currently considered an essential feature of the 
T cell response.2 However, degenerate recognition also has been implicated in the 
onset of autoimmune diseases like multiple sclerosis (MS). According to the 
molecular mimicry concept, degenerate recognition of microbial antigens can lead to 
crossrecognition of self peptides (reviewed by Wucherpfennig et al.).3 Concurrently, 
crossreactive T cell recognition is exploited by using altered peptide ligands (APL) 
for experimental immunotherapy in autoimmune diseases.4-6 
 
A limited number of T cell receptor (TCR) crystal structures shed light on some 
characteristics of crossrecognition. It was concluded that poor shape 
complementarity accounted for a high level of plasticity, and adjustments in the TCR 
surface could provide the possibility to accommodate many different peptides.7,8 
Furthermore, focusing of the TCR on only a few conserved peptide residues would 
leave the other peptide residues indifferent.9 However, in general, it appeared to be 
difficult to establish clear relationships between the structure of the MHC-peptide 
complex and the degree of degeneracy of T cell recognition. 
 
The level of T cell crossreactivity has important implications for recognition of 
modified peptides. Peptide alterations can occur as part of posttranslational 
modification processes, such as phosphorylation, methylation, deamidation, 
deimination/citrullination, and glycosylation (reviewed by Doyle et al.).10 Some of 
these events have been associated with the development of autoimmunity. It has 
been shown that lysine can be hydroxylated after which it can be glycosylated by a 
galactose residue or the disaccharide glucose-galactose.11 Glycosylation of lysine 
residues in a disease associated collagen type II T cell epitope is of importance in the 
development of collagen induced arthritis, as the modified epitope is specifically 
recognized.12 Furthermore, excessive transformation of citrulline residues from 
arginine residues occurs during rheumatoid arthritis,13,14 as well as in multiple 
sclerosis.15 The ratio of citrullinated myelin basic protein (MBP) over non-
citrullinated MBP is increased in MS patients.15 
 
To study the specificity of the T cell response at the molecular level, we applied 
selected alterations to peptide sequence 72-85 of guinea pig MBP (gpMBP72-85, 
sequence QKSQRSQDENPV), based on posttranslational modification concepts. 
GpMBP72-85 is the immunodominant T cell epitope in gpMBP induced experimental 
autoimmune encephalomyelitis (EAE) in Lewis rats, which resembles human MS.16 
The amino acid residues of the three major TCR contact residues were altered in 
three different ways. Large modifications (glycosylation) were applied at the ends of 
the peptide, small modifications were made at the center of the peptide (citrulline, 
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ornithine), and unmodified side chains of TCR contact residues were reoriented in 
space. All these alterations resulted in significantly impaired crossreactivity. In a 
systematic way, the fine specificity of the T cell populations specific for the modified 
peptides was studied. We investigated which structural elements were recognized by 
the TCR with a set of additional compounds gradually changing the epitope. These 
results imply a limited plasticity in T cell recognition, in contrast with the present 
view of intrinsic degeneracy of the T cell response. 
 
 
Materials and methods 
 
Rats 
Male inbred Lewis rats (7 weeks of age), were obtained from Universiteit Maastricht 
(the Netherlands). 
 
Peptide synthesis and modification 
Nomenclature for modified peptides derived from wild type (WT) peptide 
(gpMBP72-85): the native amino acid residue changed is indicated first with the 
three-letter code followed by the relative position in the peptide, after which the new 
building block is specified (e.g., in peptide Arg5Cit, arginine at relative position 5 is 
replaced by citrulline). Peptoid residues are indicated with the letter N preceding the 
three-letter code. WT peptide (sequence QKSQRSQDENPV, N-terminally acetylated 
and C-terminally amidated, Chapter 2)17 was synthesized on an automated peptide 
synthesizer (model 433A, Applied Biosystems) according to general procedures as 
described before.18 Modified peptides Arg5Cit and Arg5Orn were synthesized 
analogously. Peptides Arg5Lys, Lys2Gly, Arg5Gly, Asp8Gly, Lys2Ala, Arg5Ala, 
Asp8Ala, and ovalbumin323-339 (OVA323-339, control peptide) were synthesized by 
automated simultaneous multiple peptide synthesis.19 Peptoid-peptide hybrids 
Lys2NLys, Arg5NArg, and Asp8NAsp were synthesized as described before 
(Chapter 4).20 Peptoid-peptide hybrids Lys2NAla, Arg5NAla, and Asp8NAla were 
synthesized as above mentioned peptoid-peptide hybrids.21 Glycopeptides 
Lys2Gln(Gal) and Asp8Asn(Gal) were synthesized according to a new synthesis 
method as has been described recently.22 All modified peptides were purified by 
reversed HPLC (C18) analysis when necessary, and checked by mass spectrometry 
analysis. 
 
T cell clone and proliferation assay 
Isolation and maintenance of T cell clone Z1a has been described previously.23 This T 
cell clone was isolated after immunization with gpMBP and maintained by cyclic re-
stimulation with gpMBP. It specifically recognizes the gpMBP72-85 peptide. 
Proliferation was measured in flat bottom 96 wells microtiter plates (Costar). Each 
well contained 2x104 T cells, 1x106 irradiated (3000 rads) freshly isolated thymocytes 
as antigen presenting cells (APCs), and various amounts of antigens (modified 
peptides) in a total volume of 200 µl Iscove’s modified Dulbecco’s medium (IMDM, 
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Invitrogen), supplemented with 2 mM L-glutamine, 50 µM β-mercaptoethanol, 50 
U/ml penicillin, 50 U/ml streptomycin and 2% heat inactivated normal rat serum 
(NRS). After 3 days of culturing (37° C, 5% CO2), [3H]-thymidine (0.4 µCi/well, 
Amersham) was added and cells were cultured for another 18-20 hours. Cells were 
harvested on fiberglass filters and [3H]-thymidine incorporation was measured by 
liquid scintillation counting (Wallac Oy). Proliferation is expressed as stimulation 
index (SI), proliferation in presence of antigen divided by background proliferation 
without antigen ± standard deviation (SD) of triplicate samples. 
 
Modified peptide immunization and T cell isolation 
T cell responses were induced by subcutaneous injection of 50 µl of an 1:1 emulsion 
of an aqueous solution of WT peptide or modified peptide and complete Freund’s 
adjuvant (CFA, 4 mg/ml Mycobacterium tuberculosis in oil, Difco) in each hind foot 
pad (in total 100 µg peptide/rat). At day 10 popliteal lymph nodes were isolated and 
single cell suspensions were prepared. T cells (2x105 lymph node cells/well) were 
tested for proliferative responses as described above, using 5% fetal calf serum (FCS, 
Bodinco) instead of NRS. Proliferation is expressed as mean SI ± standard error of the 
mean (SEM) of number of animals. 
 
MHC-peptide binding assay 
The MHC binding capacity of the compounds was determined using a direct MHC-
peptide binding assay, as has been described before.24 Briefly, a concentration range 
(0-256 µM) of competitor (modified peptide) was incubated together with 
biotinylated marker peptide (gpMBP72-85) and detergent solubilized MHC class II 
molecules (RT1.BL) for 40 hours at room temperature and pH 5, in the presence of a 
protease inhibitor mix. The MHC-peptide mixtures were analyzed via non-reducing 
SDS-PAGE and Western blotting. Marker peptide-MHC binding was visualized by 
enhanced chemoluminescence. Affinity was expressed as IC50, the concentration of 
competitor resulting in 50% inhibition of binding of the marker peptide. 
 
Molecular modeling 
Starting point for visualization of the peptoid-peptide hybrid structures was the 
structure of the MHC class II RT1.BL molecule complexed with WT peptide, modeled 
by homology to the I-Ak/HEL peptide complex (Chapter 3).25,26 The side chains of 
the amino acid residues Lys2, Arg5, and Asp8 in the WT peptide were cut off, and 
the side chains were reconnected to the preceding backbone nitrogen atom (using the 
programme Insight II, Accelrys), without taking into account the surrounding MHC 
molecule. 
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Results 
 
Amino acid modification impairs monoclonal and polyclonal T cell recognition 
The effect of amino acid modifications on T cell recognition (proliferation) was used 
to investigate TCR plasticity. To avoid indirect effects we chose to change amino 
acids that could directly interact with the TCR (TCR contact residues). In gpMBP72-
85 (WT) the TCR contact residues have been determined to be lysine at relative 
position 2 (Lys2), Arg5, and Asp8 (Chapter 3).25 Three types of alterations were 
applied. Large modifications at positions 2 and 8 were accomplished by replacement 
with a galactosylated Gln (Gln(Gal)) or Asn (Asn(Gal)) residue, respectively 
(Lys2Gln(Gal), Asp8Asn(Gal)). In the center of the peptide at position 5 small 
modifications were applied by replacement of the Arg residue by a citrulline (Cit) or 
ornithine (Orn) residue (Arg5Cit, Arg5Orn). Finally, the side chains at positions 2, 5 
and 8 were not altered, but shifted to create a three-dimensionally different epitope. 
This was accomplished using peptoid residues, creating peptoid-peptide hybrids 
(Lys2NLys, Arg5NArg, Asp8NAsp). In peptoid residues the side chain is shifted to 
the backbone amide nitrogen atom from the α-carbon atom in an amino acid 
residue.27  
 
T cell clone Z1a, specific for gpMBP72-85, was used to investigate recognition of the 
modified peptides (Figure 1). WT peptide induced a concentration dependent 
proliferative response. Of the modified peptides only Asp8Asn(Gal) and Lys2NLys 
FIGURE 1. Proliferative response of T cell clone Z1a to WT peptide and modified peptides. 
Proliferative responses of T cell clone Z1a were tested using a concentration range (1, 10, 50, and
100 µg/ml) of WT peptide (gpMBP72-85), control peptide OVA323-339, and the modified
peptides. Proliferation is expressed as SI ± SD of triplicate samples. Data are from a
representative experiment (n=4). 
Limited plasticity in T cell recognition 
69 
caused weak proliferation at very high concentrations. To compare the response of 
the T cell clone with a polyclonal response, rats were immunized with WT peptide. 
Ten days after immunization, before rats developed clinical signs of EAE, popliteal 
lymph node cells (PLNCs) were assessed for proliferative responses to WT peptide 
and the modified peptides (Figure 2). Although WT peptide was recognized 
efficiently, no significant responses to the modified peptides were detected. WT 
peptide recognition was considered specific, as PLNCs from control peptide 
(OVA323-339) immunized animals did not respond to WT peptide or any of the 
modified peptides but the immunizing peptide itself (data not shown). These data 
indicate that the plasticity of both the T cell clone and the polyclonal response is 
limited. 
 
The question arose as whether the absence of crossreactive responses was due to a 
decreased MHC binding affinity of the modified peptides caused by the 
modification. Competition assays using isolated MHC class II RT1.BL molecules 
revealed that Lys2Gln(Gal) and Asp8NAsp displayed an intermediate affinity 
compared to WT peptide (high affinity, Table I), while Lys2NLys and Arg5NArg 
displayed a low affinity (Chapter 4).20 Modified peptides Asp8Asn(Gal), Arg5Cit, 
and Arg5Orn bound RT1.BL with an affinity comparable with WT peptide (Table I). 
Lower MHC binding affinity could therefore not be the general explanation for the 
absence of crossrecognition. 
FIGURE 2. Proliferative responses of popliteal lymph node cells to WT peptide and modified
peptides after WT peptide immunization. 
Lewis rats were immunized with 100 µg WT peptide and ten days after immunization popliteal
lymph node cells were tested for proliferative responses to WT peptide, control peptide
OVA323-339, and modified peptides (5 and 20 µg/ml). Proliferation is expressed as mean SI ±
SEM of three animals. Data are from a representative experiment (n=2-3). Responses above SI 2
(dashed line) are considered positive. 
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Table I. MHC class II binding affinities of peptide variants.a 
 
 
Compound 
 
MHC binding affinitya 
 
  
IC50 (µM)b 
 
Affinity category 
 
 
WT 
 
≤ 8c 
 
high 
Lys2Gln(Gal) 16-32 intermediate 
Asp8Asn(Gal) ≤ 8 high 
Arg5Cit ≤ 8 high 
Arg5Orn ≤ 8 high 
Lys2NLys ≥ 227c low 
Arg5NArg ≥ 256c low 
Asp8NAsp 16-32c intermediate 
 
 
aMHC binding affinity was determined using an MHC-peptide 
binding assay. 
bIC50, the concentration of competitor resulting in 50% inhibition of 
MHC binding of the marker peptide. 
cData published before (Chapter 4).20 
 
 
TCR recognizes a combination of amino acid side chain and sugar 
T cell recognition of glycosylated residues in the peptide was examined by 
modification of the peptide with galactose residues. This large modification was 
applied at the TCR contact residues N-terminally at position 2, and C-terminally at 
position 8 in the peptide (Figure 3). To investigate the crossreactivity of T cells 
reactive to a glycosylated peptide, Lewis rats were immunized with Lys2Gln(Gal) or 
Asp8Asn(Gal) and ex vivo PLNCs were tested for proliferative responses. A 
concentration dependent response was seen to the immunizing glycopeptide, 
indicating that these compounds were immunogenic (Figure 4). Lys2Gln(Gal) 
reactive T cells did not recognize WT peptide, while after Asp8Asn(Gal) 
immunization only low concentrations of WT peptide induced some proliferation. 
These data indicate that the amino acid modification was too large to elicit significant 
crossreactive responses. No recognition was seen of the glycopeptide that was 
glycosylated at the other position than the immunizing glycopeptide, indicating that 
the galactose residue was not recognized independently from the peptide. It can be 
concluded that both the sugar and the amino acid side chain are recognized together 
by the TCR. 
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FIGURE 3. Structure comparison of WT peptide and glycosylated peptides Lys2Gln(Gal) and
Asp8Asn(Gal). 
Two-dimensional structures are shown of the peptidyl fragments at positions 2 (A) and 8 (B) in
WT peptide, and modified peptides Lys2Gln(Gal) and Asp8Asn(Gal). The amino acid residue
shown in the WT peptide was replaced by a galactosylated Gln or Asn residue. 
FIGURE 4. Proliferative responses of popliteal lymph node cells after immunization with
glycolysated peptides. 
Proliferative responses of popliteal lymph node cells were assessed ten days after immunization
with glycopeptides Lys2Gln(Gal) (A) and Asp8Asn(Gal) (B). Shown are the responses to control
peptide OVA323-339, WT peptide, immunizing glycopeptide, and the other glycopeptide that is
glycosylated at a different position. Proliferation is expressed as mean SI ± SEM of three
animals per immunizing glycopeptide. Responses above SI 2 (dashed line) are considered
positive. 
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Small modifications in the center of the peptide are discriminated by the TCR 
Next, we investigated the effect on T cell recognition of small modifications in size in 
the center of the peptide. In amino acid residue arginine at position 5 in the WT 
peptide the guanidinium group (CNH) was changed into a carbonyl group (CO), 
creating a citrulline residue (Cit, Figure 5). As a result this new side chain has no 
basic properties. In another modified peptide, the amide moiety (C(O)NH2) of the 
citrulline side chain was omitted to give a side chain as present in ornithine (Orn, 
Figure 5). This side chain is basic due to the amine group, but when positively 
charged, the center of the positive charge in the ornithine side chain is closer to the 
backbone than the positive charge of the original arginine side chain, where the 
‘center of charge’ is located at the carbon atom in the guanidinium group. 
Interestingly, T cells from rats immunized with Arg5Cit or Arg5Orn only recognized 
the immunizing peptide (Figure 6). Despite the small differences, WT peptide and 
the other modified peptides were not recognized, including Arg5Lys of which the 
positively charged lysine side chain is one CH2 longer than the ornithine side chain, 
resulting in approximately the same center of charge as in the arginine side chain. 
These data again indicate that the plasticity of the T cell response is limited. 
 
Side chain shifting creates a different epitope for the TCR 
In a last approach, using peptoid residues, we did not change the nature of the side 
chains but the position. Peptide WT and peptoid-peptide hybrids Lys2NLys, 
Arg5NArg, and Asp8NAsp were modeled to obtain an impression of their three-
dimensional structures (Figure 7A). Starting from the model of the WT peptide 
bound to MHC class II molecule RT1.BL (Chapter 3),25 the structures of the peptoid-
peptide hybrids were modeled by cutting off the side chain at the α-carbon atom of 
the amino acid and reattaching it to the backbone amide nitrogen atom. Compared to 
the WT peptide, the direction of the peptoid side chains in the peptoid-peptide 
hybrids changed (Cα-C-N-H torsion angles in the WT peptide were –65º at position 2, 
–23º at position 5, and –19º at position 8), due to the polyproline type II twist of 
FIGURE 5. Structure comparison of WT peptide and modified peptides changed at position 5. 
Two-dimensional structures are shown of the peptidyl fragments at positions 5 in WT peptide,
and modified peptides Arg5Cit and Arg5Orn. The amino acid residue shown in the WT peptide
was replaced by the citrulline or ornithine residue. 
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peptides bound to MHC class II molecules.28 The models of the structures indicated 
that the proximal parts of the peptoid side chains, close to the backbone, were turned 
away from the TCR, and the backbone would become within the reach of the TCR. 
To investigate the T cell recognition of peptoid residues into detail, several peptoid-
peptide hybrid- and modified peptides at positions 2, 5, and 8 were synthesized, with 
similar backbone structures as the earlier peptoid-peptide hybrids (referred to as 
backbone mimics, Figure 7B). For example in Lys2NAla the side chain on the 
backbone nitrogen atom was shortened to NAla as compared to Lys2NLys. In 
Lys2Gly, the side chain was further cut off, i.e., absent. In Lys2Ala a short side chain 
(methyl) was present on the backbone α-carbon atom. 
 
The similarity between the synthesized backbone mimics and the peptoid-peptide 
hybrids with shifted side chains was confirmed by crossreactivity studies. Figure 8 
shows that after Lys2NLys, Arg5NArg, or Asp8NAsp immunization, besides the 
immunizing peptoid-peptide hybrid, the glycine substituted peptides, and, less 
pronounced, the alanine substituted peptides and the NAla peptoid-peptide hybrids 
were recognized. WT peptide differed too much from the immunizing peptoid-
peptide hybrids, as was shown by the lack of recognition. The glycine substituted 
peptides were recognized equally well as (or better than) the immunizing peptoid-
peptide hybrids. As can be seen in Figure 7B, e.g., Lys2Gly presented to the TCR the 
same backbone structure at position 2 as Lys2NLys (i.e., N-Cα-C). Lys2NAla also 
FIGURE 6. Proliferative responses of popliteal lymph node cells after immunization with
modified peptides changed at position 5. 
Proliferative responses of popliteal lymph node cells were assessed ten days after immunization
with modified peptides Arg5Cit (A) and Arg5Orn (B). Shown are the responses to control
peptide OVA323-339, WT peptide, immunizing peptide, and other modified peptides changed
at position 5. Proliferation is expressed as mean SI ± SEM of three animals per immunizing
peptide. Responses above SI 2 (dashed line) are considered positive. 
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presented that same structure, but its MHC binding affinity was much lower than 
that of Lys2Gly (Chapters 3 and 4).20,25 Lys2Ala was recognized less efficiently than 
Lys2Gly, which might be explained by the presence of a methyl group, which is 
absent in Lys2NLys. At position 5 the results might be explained in a similar way, 
but at position 8 it is not understood why Asp8NAla was not recognized equally well 
as Asp8Gly, since they both showed high MHC binding affinity. In summary, it can 
be concluded that shifting the side chains of TCR contact residues alters the epitope 
that is presented to the TCR. Furthermore, T cells are sensitive to modifications 
applied to the backbone of the peptide at TCR contact residue positions. 
 
FIGURE 7. Three-dimensional structures of WT peptide, peptoid-peptide hybrids, and
backbone mimics. 
(A) Three-dimensional structures of WT peptide and peptoid-peptide hybrids Lys2NLys,
Arg5NArg, and Asp8NAsp (only polar hydrogen atoms are shown). The MHC (below) and the
TCR (above) are not shown for clarity. The arrows indicate the positions of the peptoid
residues. WT peptide structure was modeled by homology to the HEL peptide in I-Ak (Chapter
3).25,26 Structures of the peptoid-peptide hybrids were created by removal of the side chain from
the α-carbon atom of the amino acid residue and reattaching it to the backbone nitrogen atom.
(B) Details of the structures from panel (A) and the peptoid-peptide hybrid and backbone
mimics at the same position. Only peptidyl fragments of peptoid residues and amino acid
residues are shown as they are present in the peptoid-peptide hybrids or peptides. 
 
Limited plasticity in T cell recognition 
75 
 
 
FIGURE 8. Proliferative responses of popliteal lymph node cells after immunization with
peptoid-peptide hybrids. 
Proliferative responses of popliteal lymph node cells were assessed ten days after immunization
with peptoid-peptide hybrids Lys2NLys (A), Arg5NArg (B), and Asp8NAsp (C). Shown are the
responses to control peptide OVA323-339, WT peptide, immunizing peptoid-peptide hybrid,
and crossreactivity to backbone mimics changed at the same position as the immunizing
peptoid-peptide hybrid. Proliferation is expressed as mean SI ± SEM of three animals per
immunizing peptoid-peptide hybrid. Data are from a representative experiment (n=2).
Responses above SI 2 (dashed line) are considered positive. 
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Discussion 
 
Degenerate antigen recognition is considered an intrinsic property of T cells.2,29 This 
implicates that alterations in the MHC-peptide complex still should lead to T cell 
recognition, although the response of the T cell may be altered.30 We, however, found 
highly specific T cell responses as both large modifications as the introduction of 
sugars, and very small modifications in terms of size, such as one atom difference in 
the center of the peptide (Arg5Cit), and side chain shifting resulted in lack of 
crossrecognition. Specific T cell recognition has important implications regarding 
posttranslational modifications that can alter the epitope. Posttranslational 
glycosylation, for example, causes rather large alterations in peptides. Interestingly, 
specific T cell recognition of glycosylated peptides and aberrant glycosylation have 
been associated with various diseases such as cancer, allergy, and autoimmune 
diseases.10,31 In the mouse model of collagen induced arthritis, and in rheumatoid 
arthritis patients the majority of collagen specific T cells specifically recognize a 
glycosylated epitope.32 The galactose of this collagen type II T cell epitope is attached 
to the hydroxyl group of a hydroxylated lysine residue.11 In the present study we 
mimicked this modification by N-linking a galactose residue to the side chain of a 
glutamine residue. Indeed, also in our study, the non-glycosylated WT peptide was 
not recognized by glycopeptide specific T cells, and vice versa. 
 
Studies with glycopeptides concerning the fine specificity in T cell recognition of 
peptide bound sugar residues, showed strong specificity for sugar hydroxyl 
groups.32-37 It was demonstrated that glycopeptide specific T cells recognize both the 
sugar residue and amino acid side chain to which it is attached in a combined 
manner, as modifications of this amino acid side chain or the sugar residue were not 
tolerated.11,33,34,37 Also our study indicates that the T cell recognizes the sugar residue 
and the amino acid side chain in a combined way, as the same sugar residue attached 
to an asparagine residue at a different position was not crossrecognized. 
 
Citrullination, another posttranslational modification, is the conversion of arginine 
into citrulline, when bound in a peptide, and is accomplished by deimination by the 
enzyme peptidylarginine deiminase.38 Citrullination occurs in each individual, but 
extensive citrullination of MBP is implicated in certain diseases like MS.15 In 
Marburg’s disease, an acute form of MS, arginine 79 is converted to citrulline,39,40 
while this position is unaffected in normal MS patients.41 In the present study, we 
introduced a citrulline residue at the corresponding position in the gpMBP72-85 
epitope (WT). T cells specific for the WT peptide containing the arginine residue, did 
not recognize the citrulline containing peptide. In the WT peptide the arginine side 
chain is positively charged, but in modified peptide Arg5Cit this side chain has 
become neutral, possibly explaining the lack of crossrecognition. Although in 
modified peptide Arg5Orn the positive charge is present at a position closer to the 
backbone, and in peptide Arg5Lys the center of charge position resembles arginine 
more closely, none of these peptides, were recognized by the WT peptide specific T 
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cells (Arg5Lys data not shown). These data suggest a highly specific T cell repertoire 
in the Lewis rat induced either with gpMBP72-85 or one of the modified peptides. 
Furthermore, it has been shown before that citrullination is not implicated in EAE, 
where the disease is induced actively, e.g., by immunization with guinea pig 
MBP.42,43 Our data confirm that in rats that develop EAE no citrulline is present at 
that particular position. 
 
The third group of modifications we investigated, was the redirection of the side 
chains of the three TCR contact residues in the WT peptide in their orientation to the 
TCR. The side chains were shifted along the peptide backbone one atom position to 
the N-terminus, using peptoid-peptide hybrids. Although no alterations were 
induced in the side chain, the peptoid-peptide hybrids were not crossrecognized 
after WT peptide immunization and vice versa. It is unclear whether the TCR of the 
WT specific T cell population did not recognize the peptoid-peptide hybrid due to a 
position specific recognition of the amino acid side chains, or whether the peptoid 
side chains were not able to contact the TCR. Also replacement of an L amino acid for 
a D amino acid alters the direction of the amino acid side chain. In agreement with 
our results, peptides containing D amino acids at relative positions 2, 5 and 8 were 
not recognized by monoclonal and polyclonal WT specific T cells, and no 
crossreactive responses to WT peptide were observed after immunization with D 
amino acid modified peptides.44 We showed that the backbone mimics which 
resembled the three-dimensional structure of the immunizing peptoid-peptide 
hybrids more closely, were recognized best, taken into account the differences in 
MHC binding capacity. From these results we conclude that the TCRs of the induced 
T cell populations could discriminate between small changes in the backbones of the 
newly formed epitope. In contrast, two other reports on backbone modifications of 
MHC class II bound peptides, however, showed that the T cell tolerated the 
introduction of an ethylenic bond,45 and also aza amino acids.46 
 
Summarizing, we found limited T cell plasticity as both small and large alterations in 
an immunogenic peptide implicated in an autoimmune disease model, caused lack of 
crossrecognition. Our findings bear implications for the correct definition of epitopes 
taking into account posttranslational modifications, and are of importance for the 
design of crossreactive peptides for experimental therapy. 
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Abstract 
 
Therapeutic intervention in experimental autoimmune diseases by modulation of the 
T cell mediated autoimmune response has been accomplished in the past using 
altered peptide ligands (APLs). These peptides are usually created by applying 
alterations to the T cell epitope recognized by the autoaggressive T cells. In this 
study, we investigated whether it was possible to design APLs in a rational way, 
using knowledge of molecular interaction in the MHC-peptide-T cell receptor (TCR) 
complex, for the therapeutic intervention in experimental autoimmune 
encephalomyelitis (EAE). Additionally, the value of peptidomimetic modification 
and alterations based on posttranslational modifications for the design of APLs was 
examined. Based on a molecular model of the MHC-peptide complex, the T cell 
receptor contact residues were identified and selected alterations were applied. The 
designed APLs were tested for MHC binding capacity, T cell recognition, blocking of 
the autoreactive T cell response, immunogenicity, encephalitogenicity, and 
therapeutic activity. Based on the results of the in vitro assays, it was expected that 
some of our APLs would be able to modulate EAE. Nevertheless, none of these APLs 
displayed clear therapeutic activity in vivo. Thus, rational design of modified 
peptides for immunotherapy has to await further insights into the relationships 
between structure and peptide/peptidomimetic induced T cell activation, and until 
that, there is no possibility to take advantage of the tailor made origin of 
peptidomimetics. 
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Introduction 
 
T cells play an important role in the pathogenesis of many autoimmune diseases, 
such as rheumatoid arthritis and multiple sclerosis. Antigen specific activation of 
CD4+ T cells takes place via interaction of the T cell receptor (TCR) on the T cell with 
an antigen derived peptide bound to a major histocompatibility complex (MHC) 
class II molecule, on an antigen presenting cell (APC). The antigenic peptide is bound 
to the MHC class II molecule in a polyproline type II twist.1 As a result, TCR 
interaction with peptide amino acid side chains is limited to a few TCR contact 
residues, while the other peptide amino acid side chains are (partially) buried in 
pockets in the MHC class II molecule.1 
 
Altered peptide ligands (APLs) have been defined as peptides, in which amino acid 
replacements cause a different activation of the T cell, as a result of the modified 
interaction with the TCR.2 In a broad interpretation, APLs can be classified as super 
agonists, full agonists, weak agonists, partial agonists, antagonists, or null 
compounds.3,4 Weak agonists are able to induce full T cell stimulation at high 
concentrations, while partial agonists induce some but not all T cell functions (e.g., 
cytokine secretion without proliferation). T cell stimulation caused by the native 
ligand can be blocked, either actively by a partial agonist inducing anergy, or 
passively, by an antagonist or an MHC blocker. These characteristics of APLs have 
been successfully exploited for treatment of experimental autoimmune diseases, such 
as experimental autoimmune encephalomyelitis (EAE).3,5 Apart from this direct 
effect on the T cell specific for the unaltered (auto)antigenic peptide, an APL can also 
indirectly modulate the T cell response. APL immunization may induce expansion of 
a new T cell population that can modulate the (auto)immune response via immune 
deviation and/or the bystander mechanism.6 
 
Traditionally, the design of APLs has been based on systematically substituting all 
amino acid residues in the disease associated T cell epitope into alanine or other 
amino acids and subsequently monitoring the effects of the APLs on autoreactive T 
cells in vitro, and disease inhibition in vivo.7 Recently, posttranslational 
modifications that can alter a T cell epitope were used as an inspiration source for 
APL design. Wellner et al. reported on the first stages towards the development of an 
APL, based on a modified glycosylated peptide.8 Also other peptidomimetic building 
blocks have been incorporated.9-13 Peptidomimetic APLs could have major 
advantages for immunotherapeutic usage compared to peptidic APLs. 
Peptidomimetics are more stable than peptides.14,15 Furthermore, tailor made 
peptidomimetic building blocks could be incorporated in the peptide, in order to 
change the peptide-TCR interaction in a desired and subtle manner, while an amino 
acid replacement may be too large. Although several reports investigating the T cell 
recognition of MHC class II binding glycosylated peptides8,16-21 and 
peptidomimetics9,11-13,22,23 have been published, so far, to our knowledge, no data are 
reported of the therapeutic effect of such compounds. 
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Besides large libraries of modified peptides or peptidomimetics that have been 
synthesized in order to identify APLs in a trial and error approach,24-26 more recently 
knowledge of crystal structures of MHC class II molecules and TCRs has been used 
to rationally design APLs.27,28 Rational design describes and employs structure-
activity relationships for the prediction of a compound with the desired activity. In 
the present paper, we combine the knowledge of the interaction in the MHC-peptide-
TCR complex with organic synthesis of modified amino acids providing tailor made 
building blocks, in an attempt to rationally design APLs. Using information from 
crystal structures, we previously created a computer model of the MHC class II 
RT1.BL molecule in complex with the guinea pig myelin basic protein peptide 
sequence 72-85 (gpMBP72-85) (Chapter 3).29 Peptide gpMBP72-85 (WT) is an 
immunodominant epitope in EAE.30 The three TCR contact residues in the gpMBP72-
85-RT1.BL complex were established to be Lys73 at relative position 2 (Lys2), Arg5, 
and Asp8 (Chapter 3)29 and we chose to change these residues in different 
approaches (large and small modifications), using tailor made building blocks 
(Chapter 5).31 These APLs were evaluated using a broad range of in vitro and in vivo 
tests. Although some of the APLs were promising in the in vitro assays, in vivo 
testing revealed lack of the desired therapeutic effect. The possibilities and 
limitations are discussed of this attempt to rationalize which interactions should be 
modified and in which way to design a therapeutic APL. 
 
 
Materials and methods 
 
Rats 
Male inbred Lewis rats (6 weeks of age, 200 g), were obtained from Universiteit 
Maastricht (the Netherlands). 
 
Antigens and synthesis 
Syntheses of peptide guinea pig myelin basic protein sequence 72-85 (gpMBP72-85, 
sequence QKSQRSQDENPV) and APLs derived from this wild type (WT) peptide 
have been described before (Chapters 4 and 5).31,32 Nomenclature is as follows: the 
native amino acid residue that is changed is indicated first with the three letter code 
followed by the position in the peptide, and specification of the new (modified) 
amino acid residue (e.g., in peptide Arg5Cit, arginine at relative position 5 is 
replaced by citrulline). Peptoid residues are indicated with the letter N preceding the 
three letter code. All these peptides/peptidomimetics were N-terminally acetylated 
and C-terminally amidated (Chapter 2).33 Peptides and peptidomimetics were 
purified by reversed phase HPLC (C18) analysis when necessary, and checked by 
mass spectrometry analysis. Complete protein gpMBP was isolated from guinea pig 
spinal cord.34 
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Polyclonal T cell proliferation assay 
T cell responses were induced by subcutaneous injection of 50 µl of an 1:1 emulsion 
of an aqueous solution of gpMBP and complete Freund’s adjuvant (CFA, 4 mg/ml 
Mycobacterium tuberculosis in oil, Difco) in each hind foot pad (in total 50 µg 
gpMBP/rat). At day 10 popliteal lymph nodes were isolated and single cell 
suspensions were prepared. Proliferation was measured in flat bottom 96 wells 
microtiter plates (Costar). Each well contained 2x105 lymph node cells and APL (5 
and 20 µg/ml) in a total volume of 200 µl Iscove’s modified Dulbecco’s medium 
(IMDM, Invitrogen), supplemented with 2 mM L-glutamine, 50 µM β-
mercaptoethanol, 50 U/ml penicillin, 50 U/ml streptomycin and 5% heat inactivated 
fetal calf serum (FCS, Bodinco). After 3 days of culturing (37° C, 5% CO2), [3H]-
thymidine (0.4 µCi/well, Amersham) was added and cells were cultured for another 
18-20 hours. Cells were harvested on fiberglass filters and [3H]-thymidine 
incorporation was measured by liquid scintillation counting (Wallac Oy). 
Proliferation is expressed as mean stimulation index (SI), proliferation in presence of 
antigen divided by background proliferation without antigen ± standard error of the 
mean (SEM) of individual SIs of animals tested. 
 
T cell clone and blocking assay 
Isolation and maintenance of T cell clone Z1a has been described previously.35 This T 
cell clone was isolated after immunization with gpMBP and maintained by cyclic re-
stimulation with gpMBP. It specifically recognizes the gpMBP72-85 (WT) peptide. 
Freshly isolated APCs (thymocytes, irradiated at 3000 rads, 7.5x105 per well) were 
pre-incubated (1 h, 37° C, 5% CO2, in flat bottom 96 wells microtiter plates (Costar)) 
with various amounts of APLs or control peptides (0, 10, 25, 50, and 100 µg/ml) in a 
total volume of 100 µl IMDM, supplemented with 2 mM L-glutamine, 50 µM β-
mercaptoethanol, 50 U/ml penicillin, and 50 U/ml streptomycin. Subsequently, Z1a 
T cells (2x104 per well), and a suboptimal dose of WT peptide (to an end 
concentration of 0.1 µg/ml) were added and this was cultured in a total volume of 
200 µl IMDM (supplemented as above), with the addition of heat inactivated normal 
rat serum (NRS, 2% in total). Cells were cultured for 3 days, and harvested as 
described above. Proliferation is expressed as SI ± standard deviation (SD) of 
triplicate samples. 
 
EAE induction, co-immunization and clinical evaluation 
EAE was induced by immunization with a subcutaneous injection of 50 µl of an 1:1 
emulsion of an aqueous solution of WT peptide or APL (2 mg/ml) and CFA (4 
mg/ml Mycobacterium tuberculosis in oil) in each hind foot pad (in total 100 µg WT 
or APL per rat). Therapeutic co-immunization experiments were performed as 
described before.7 Briefly, rats were co-immunized by subcutaneous injection of 50 µl 
of an 1:1 emulsion of an aqueous solution containing WT peptide (1 mg/ml) and 
APL/control peptide (10 mg/ml), and CFA (4 mg/ml Mycobacterium tuberculosis in 
oil) in each hind foot pad (in total 50 µg WT peptide and 500 µg APL per rat). The 
weight of the animals and clinical signs of EAE were monitored daily according to a 
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scale from 0 to 4: 0, no signs; 0.5, significant weight loss; 1, limp tail; 2, hind leg 
weakness; 3, paraplegia; 4, paraplegia with fore limb weakness, moribund condition. 
 
 
Results 
 
Design of APLs  
For APL design we used the gpMBP72-85 peptide and modified the three previously 
defined TCR contact residues (Chapter 3).29 In the central TCR contact residue of the 
peptide (Arg5) we applied a small modification in size by changing one atom using a 
citrulline residue instead of an arginine residue (Arg5Cit) (Figure 1). As a result of 
the replacement of the O atom for the NH moiety, the basic nature of the side chain 
has disappeared. In Arg5Orn, in which the side chain is further shortened, the 
basicity is restored (Figure 1). Larger alterations were applied at the N- and C-
terminal TCR contact residues of the peptide. At position 2, a glycosylated, i.e., 
galactose containing amino acid residue (Gln(Gal)) was introduced (denoted as 
Lys2Gln(Gal)) and at position 8 a galactose containing asparagine residue 
(Asp8Asn(Gal)) (Figure 1). Peptoid residues were used to create peptoid-peptide 
hybrids (Lys2NLys, Arg5NArg, Asp8NAsp), with the intention to offer a slightly 
altered contact with the TCR. In a peptoid residue the same side chain is present on 
the backbone nitrogen atom as is normally present on the α-carbon atom in an amino 
acid residue.36 For investigation of the possible therapeutic APL effect in vivo, and to 
exclude non-promising APLs, a trajectory of biochemical and in vitro assays was 
followed (Figure 2). APLs that induced strong T cell proliferation, did not bind to the 
MHC class II RT1.BL molecule, or induced EAE, were not considered for evaluation 
of the therapeutic activity. A T cell blockade assay and immunogenicity studies were 
applied to elucidate the possible mechanism of APL therapeutic activity. 
 
T cell proliferation 
APLs are supposed not to induce full activation of the T cell.2 Therefore, the APLs 
were first assayed for induction of proliferation of the encephalitogenic T cell clone 
Z1a. Only APLs Asp8Asn(Gal) and Lys2NLys caused proliferation at very high 
concentration (Table I) (Chapter 5),31 suggesting a possible weak agonistic effect on 
clone Z1a. Polyclonal T cell proliferative responses to the APLs were tested by using 
lymph node cells expanded after gpMBP immunization or WT peptide 
immunization. In both cases no significant responses were observed to any of the 
APLs (Figure 3, and Chapter 5,31 respectively). 
 
MHC binding capacity 
Peptides with high MHC binding affinity could have the capability to compete with 
disease associated epitopes in vivo for MHC binding, and in this way interfere with 
the disease process.37 Our APLs were designed to change the interaction with the 
TCR, while leaving the interaction with the MHC unaltered. We have shown before  
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FIGURE 1. Schematic representation of the MHC-peptide-TCR complex, and structures of
applied modifications to this peptide. 
Interaction is displayed of peptide gpMBP72-85 (middle), bound to MHC class II molecule
RT1.BL (bottom), and the TCR of T cell Z1a (top) (upper panel). Shown are details of the two-
dimensional structures of the modifications to the TCR contact residues of peptide gpMBP72-85
(Lys2, Arg5, Asp8) applied in the APLs (lower panel). 
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that alanine and glycine substitutions at positions 2, 5, and 8 did not influence MHC 
binding capacity, and therefore the original amino acid side chains were not 
necessary for MHC binding (Chapter 3).29 As expected, for most APLs the MHC 
binding affinity was unaffected or only slightly decreased (Table I) (Chapters 4 and 
5).31,32 Two peptoid-peptide hybrids showed a strongly decreased MHC binding 
affinity, possibly caused mainly by the loss of a hydrogen bond between the peptide 
backbone and the MHC (Chapter 4).32 
 
Clarification of APL activity 
Because most APLs did not induce Z1a proliferation, it was of interest to investigate 
whether these compounds were able to inhibit Z1a proliferation induced by WT 
peptide, as this could be indicative for antagonistic activity.38 Figure 4 shows that the 
APLs did not block WT induced Z1a proliferation, while the two control peptides 
(OVA323-339 and Asp8Ala) displayed inhibitory capacity. OVA323-339, which 
shows no sequence homology to gpMBP72-85, has been used as a mere MHC class II 
blocker, while control peptide Asp8Ala is a previously defined APL derived from 
gpMBP72-85. Both peptides can interfere with EAE.7,39 
 
Apart from a direct influence on the encephalitogenic T cell population, in vivo APL 
function can also result from expansion of a novel, regulatory, subset of T cells or  
 
FIGURE 2. Flow chart showing exclusion criteria for APL development. 
The outcomes of in vitro and in vivo assays are categorized into no, weak, or strong capacity.
Additionally, using the in vitro assays, the possible APL effect was investigated. 
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Table I. Summary of experimental data. 
 
 
Compound 
 
T cell 
proliferationa 
 
MHC 
bindingb 
 
 
Inhibition of 
proliferation 
 
Immuno-
genicityb 
 
Encephali-
togenicity 
 
Therapeutic 
activity 
 
WT 
 
++ 
 
++ 
 
n.a.c  
 
++ 
 
++ 
 
n.a.c  
Lys2Gln(Gal) − + − + − − 
Asp8Asn(Gal) +/− ++ − + + n.d.d  
Arg5Cit − ++ − + − − 
Arg5Orn − ++ − ++ + n.d.d  
Lys2NLys +/− − − ++ − − 
Arg5NArg − − − ++ − − 
Asp8NAsp − + − ++ + n.d.d  
 
 
aFor exact data see reference 31 (Chapter 5). 
bFor exact data see reference 32 (Chapter 4). 
cNot applicable. 
dNot determined (see Results). 
 
from immune deviation.6 Therefore, the immunogenicity of the APLs was evaluated, 
by analyzing the specific response of isolated popliteal lymph node cells (PLNCs) to 
the immunizing APL. All APLs induced a specific T cell population (Table I), while 
no significant crossreactive responses to the WT peptide were observed (Chapter 5).31 
These data indicate that, although our APLs are not likely to act as antagonists, they 
could potentially modulate EAE indirectly, by induction of immune deviation or by 
the regulatory function of the APL specific T cell population.6 
 
Encephalitogenicity 
To analyze the possibility that APLs induced EAE, the encephalitogenicity was 
checked by immunization of Lewis rats with a high dose (100 µg) of the APL. Table II 
shows that APLs Lys2Gln(Gal), Arg5Cit, Lys2NLys, and Arg5NArg did not induce 
clinical signs of EAE. Immunization with APLs Asp8Asn(Gal), Arg5Orn, and 
Asp8NAsp, however, caused mild EAE in some animals, and we excluded these 
APLs for therapeutic intervention. 
 
Therapeutic intervention in EAE 
The final test for our candidate APLs was investigation of the capacity to inhibit WT 
induced EAE. Lys2Gln(Gal), Arg5Cit, Lys2NLys, and Arg5NArg were tested in a co-
immunization protocol. Rats received a low dose EAE inducing peptide (50 µg WT) 
together with a tenfold higher dose of APL. Unfortunately, none of the APLs could 
interfere in the disease process as no significant inhibition of clinical EAE was 
observed (Figure 5), while control peptide OVA323-339 efficiently inhibited  
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FIGURE 4. Blocking of WT induced T cell proliferation of T cell clone Z1a.  
A suboptimal concentration of 0.1 µg/ml WT was used to induce proliferation of Z1a. The
capacity to block this proliferative response was tested by pre-incubation of the APCs with a
concentration range (0, 10, 25, 50, 100 µg/ml) of the APLs or a positive control peptide
(OVA323-339 or Asp8Ala, separated by the dashed line). Proliferation is expressed as SI ± SD of
triplicate samples. Data are from a representative experiment (n=2). 
FIGURE 3. Proliferative responses of lymph node cells to WT peptide and APLs after gpMBP
immunization. 
Lewis rats were immunized with 50 µg gpMBP in CFA and ten days after immunization
popliteal lymph node cells were tested for proliferative responses to gpMBP, WT peptide,
control peptide OVA323-339, and APLs (5 and 20 µg/ml). Proliferation is expressed as mean SI
± SEM of three animals. Responses above SI 2 (dashed line) are considered positive. 
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Table II. EAE induction.a 
 
 
Compound 
 
EAE development 
 
  
Incidence 
 
Maximum severityb 
 
 
WT 
 
5/5 
 
2.1 ± 0.2 
Lys2Gln(Gal) 0/5 0 
Asp8Asn(Gal) 2/5 1.0 ± 0 
Arg5Cit 0/5 0 
Arg5Orn 2/5 0.5 ± 0 
Lys2NLys 0/5 0 
Arg5NArg 0/5 0 
Asp8NAsp 1/5 1.5 
 
 
aEAE was induced by subcutaneous injection in the hind foot pads of male 
Lewis rats (200 g) with an 1:1 emulsion of an aqueous solution containing 
100 µg WT peptide or APL and CFA.  
bMean maximum severity of diseased animals ± SEM, scale 0-4. 
 
 
development of EAE. These data were supported by the reduced response of lymph 
node cells to WT peptide after OVA323-338 co-immunization, while co-
immunization with the APLs did not cause a reduced response to WT peptide (data 
not shown). 
 
 
Discussion 
 
It has been shown previously that APLs can interfere in the course of experimental 
autoimmune diseases like EAE (reviewed in reference 3). We investigated the 
possibilities and restrictions of using knowledge from crystal structures for the 
rational design of APLs, and we analyzed the use of peptidomimetics and modified 
peptides as APLs. Although numerous suggestions have been made to exploit 
peptidomimetic compounds and altered posttranslationally modified peptides for 
treatment of autoimmune disease8,11,13,22,23 to our knowledge, no reports have been 
published showing the in vivo therapeutic behavior of such compounds. Here we 
describe an entire trajectory from the design of modified peptides as APLs, through 
biochemical and in vitro testing, to in vivo evaluation. However, despite a rational 
design, and promising outcomes of in vitro and in vivo assays, none of our APLs 
could accomplish the desired disease modulation (summarized in Table I). 
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The lack of published results regarding therapeutic intervention of 
posttranslationally modified peptides or peptidomimetics could indicate that such 
compounds might be unsuitable for APL therapy. Peptidomimetics binding to MHC 
class I designed for the induction of cytotoxic T cells have been tested for their 
therapeutic value with varying degrees of success.40,41 The underlying principle for 
the induction of an MHC class I restricted cytotoxic response in vivo, however, is 
different than for an MHC class II restricted APL to exert its in vivo effect. For 
cytotoxicity an agonistic signal through the T cell is needed, while class II binding 
APLs are supposed to induce altered T cell activation. However, the rules that 
describe the qualitative relationship between the peptide/peptidomimetic structure 
and (altered) outcome of T cell activation, are difficult to define.42,43 Crystallographic 
analyses of MHC-peptide-TCR complexes showed that small structural changes 
between agonist and antagonist peptides were responsible for the large difference in 
T cell responses. Discrimination between the agonist and the antagonist peptides was 
found to occur in a centrally located cavity.44 Another report, however, demonstrated 
that the structures of a strong agonist and an antagonist were more similar than 
structures of ligands with comparable activity.45 Closer examination of two crystal 
structures involving the antagonist, containing an alanine residue, and the agonist, 
FIGURE 5. Inhibition of EAE by co-immunization. (A) At day 0, Lewis rats were immunized
with 50 µg WT peptide in CFA (n=4), or co-immunized with 50 µg WT plus 500 µg of OVA323-
339 (n=4), Lys2NLys (n=5), or Arg5NArg (n=5) in CFA. (B) At day 0, Lewis rats were
immunized with 50 µg WT peptide in CFA (n=5), or co-immunized with 50 µg WT plus 500 µg
of Lys2Gln(Gal) (n=5), or Arg5Cit (n=5) in CFA. EAE score is displayed as mean score ± SEM of
all animals in a group. *Mean maximum severity statistically significant different from WT
immunization, as determined by Student’s t-test (p=0.0054). No statistically significant
difference for Lys2NLys (p=0.97), Arg5NArg (p=0.28), Lys2Gln(Gal) (p=0.29), or Arg5Cit
(p=0.42) co-immunization, compared to WT immunization. aOne animal in the Lys2NLys co-
immunized group was sacrificed at day 14 due to severe EAE, and one animal deceased at day
17. bTwo animals in the Arg5NArg co-immunized group deceased at day 17 and 18. cOne
animal in the WT group deceased at day 18. 
 
Rational design of modified peptides 
95 
containing a proline residue, showed a cavity at the place where the amino acid side 
chain of the proline residue resided in the agonist peptide. By the stepwise repair of 
this defect in the TCR-peptide binding interface, using N-alkylated peptidomimetic 
residues, the agonist activity could be restored.46 
 
Previously, it has been shown that the center of the peptide is recognized by the TCR 
with high specificity, while recognition of the N- and C-terminal parts of the peptide 
is less specific.42,47 In our attempt to design APLs, we applied selected alterations 
ranging from small modifications in the center of the peptide, to larger modifications 
distally in the peptide. One might speculate that if alterations to the EAE inducing 
peptide were too small, this would result in residual encephalitogenic activity, and 
when the modifications were too large, this would result in a null compound.2 This 
hypothesis, however, was not confirmed, as peptide Arg5Cit, only differing from WT 
peptide by a single hetero atom, was not encephalitogenic, while peptide Arg5Orn 
differing more atoms, showed weak encephalitogenicity. Possibly the comparison of 
similar peptides, however, cannot be simplified to size similarities, and charge 
(dis)similarities might be additionally important. However, also when charge is 
taken into account, there is no clear correlation with encephalitogenicity. Peptide 
Arg5Lys, which more closely resembles WT both in steric and charge characteristics 
than Arg5Orn does, is not encephalitogenic (unpublished data). Encephalitogenicity 
of the APLs was expected to result from the expansion of a novel encephalitogenic T 
cell population, as no crossreactivity was seen after WT immunization to the APLs, 
and vice versa (Chapter 5).31 At position 8 in Asp8NAsp the modification seemed to 
be too small (causing encephalitogenicity), therefore we designed Asp8Asn(Gal). 
However, also this APL appeared to be encephalitogenic. The fact that Asp8Ala 
displayed therapeutic effect, while the both in size and charge less altered Asp8NAsp 
and more altered Asp8Asn(Gal) did not, added to the above described 
unpredictability of APL activity. Our conclusion therefore is, that there is no 
straightforward and linear relationship between APL structure and therapeutic 
effect. 
 
Difficulties with APL design have also been encountered during two phase II clinical 
trials assessing the therapeutic value of an APL derived from MBP83-99 in multiple 
sclerosis (MS).48,49 The studies were terminated because of MS exacerbations or 
hypersensitivity reactions. The hypersensitivity was probably a consequence of too 
strong skewing of the immune response towards Th2,50 while the exacerbations 
could have resulted from the stimulation of MS inducing T cells by the APL.3 An 
APL that functions as an antagonist for one T cell, may exert agonistic activity for 
another T cell. This unpredictable behavior can be caused by different TCRs sensing 
different TCR contact residues in the same peptide. Also, peptides binding in 
different registers to the MHC class II molecule add to this complexity.3 These 
findings complicate the application of one APL for treatment of different individuals 
or even one individual. Bielekova et al. suggested that APL peptides should show 
less similarity with the native epitope to prevent crossreactivity with MS inducing T 
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cells and increase the possibility to induce a regulatory T cell population.3 It is 
unpredictable to which elements in a peptide these new T cells should react and thus 
rational design would be ineffective in this context. Also in the present report, we 
encountered similar problems in the prediction of the in vivo behavior of modified 
peptides. Until the requirements for the design of an APL and the desired in vivo 
behavior have been elucidated, the rational design of APLs remains difficult. 
Modified peptides and peptidomimetics that can be tailor made to contain desired 
alterations, have at this time no surplus value in the rational design of APLs and can 
only be used in a trial and error approach. 
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The important role of the  
MHC-peptide-T cell receptor complex 
 
In a large number of autoimmune diseases, recognition of autoantigens by T cells 
plays an important role in the disease process. The recognition of such self peptides 
can be the result of breakdown of tolerance, e.g., resulting from the recognition of 
molecular mimicry epitopes.1 Furthermore, self peptides can be posttranslationally 
modified, creating a new (auto)antigenic epitope.2 Insight into the molecular 
interactions in the complex of MHC class II, peptide and T cell receptor (TCR) is of 
utmost importance, since the specificity of the T cell mediated immune response 
originates from the level of this trimolecular interaction. This knowledge of 
molecular recognition is necessary to understand the onset and progress of 
(auto)immune disorders, and also of great importance for the design of a specific 
intervention strategy for treatment of these diseases, based on T cell modulation. In 
this chapter, first the chosen methodology to gain insight into the influence of 
peptide modification on interactions in the MHC-peptide-TCR complex is evaluated, 
followed by a summary of the structure-activity relationships for different modified 
peptides. 
 
 
Understanding molecular interactions at the  
MHC-peptide-TCR interface 
 
To acquire knowledge of the influence of peptide modifications on interactions in the 
MHC-peptide-TCR complex in order to understand the initial event of T cell 
activation, a multidisciplinary approach was used (Figure 1). A combination of 
modeling techniques together with analysis of known crystal structures and binding 
studies, organic synthesis supplying tailor made peptidomimetic/peptidic building 
blocks, chemical analysis techniques, and a broad range of biochemical, cellular and 
in vivo assays was exploited. The outcomes at different stages of this approach were 
reconsidered at the molecular level. To evaluate this approach, it is of interest to 
discuss the possibilities to identify molecular interactions, and whether this resulted 
in a better understanding of the outcome of T cell activation. 
 
Value of modeling and crystal structures 
To study the molecular interactions we used known crystal structures of MHC class 
II molecules with bound peptides, and crystal structures of MHC class I and II 
restricted TCRs that became available recently. A homology model of the MHC class 
II RT1.BL molecule with peptide gpMBP72-85 was constructed, based on the crystal 
structure of MHC class II I-Ak molecule with bound peptide (Chapter 3).3 For 
positioning of the peptide in the MHC binding groove, a simple scoring procedure 
was used. Instead of quantitatively predicting MHC binding affinity of the modified 
peptides with a scoring function, we used the homology model and crystal structures 
afterwards to qualitatively explain the MHC binding affinity that was found  
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experimentally.4 Numerous reports describing scoring functions that predict peptide-
MHC binding have been published lately (reviewed by Yu et al.),5 but the large 
number of reports may represent the lack of general applicability of these scoring 
functions. Furthermore, scoring functions may only apply to the twenty 
proteinogenic amino acids. The homology model was only used to explain large 
changes. Visualization of the three-dimensional structures in the model proved 
helpful for understanding steric hindrance of modified peptides and the MHC 
molecule (Chapter 4), as well as for the interpretation of similarities in three-
dimensional structures of a set of modified peptides (Chapter 5). Subtle structural 
consequences of modification, like the presence or absence of a hydrogen bond, were 
not deduced from the model but from crystal structures (Chapter 4).6 Although 
crystal structures may not represent the biologically active conformation, the 
accuracy at the atomic level of a homology model may be even smaller compared to 
the crystal structure, depending on the degree of homology. Furthermore, no water 
molecules were included in the homology model, that have been shown in crystal 
structures to be important for the generation of hydrogen bonds.7-11 
FIGURE 1. Flow chart showing multidisciplinary approach for study of the influence of peptide
modification on molecular interactions in the MHC-peptide-TCR complex and outcome of T cell
activation. 
Results at the different stages were reconsidered at the molecular level. 
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No crystal structure of the TCR involved was available, and with only a few TCR 
crystal structures elucidated (out of innumerable existing TCRs), a model of the TCR 
could not be built with the same reliability as the MHC molecule. Creation of a 
correct MHC-peptide-TCR interface, if possible at all, requires sophisticated 
modeling techniques and reliable homology models of MHC-peptide and TCR as an 
accurate starting point. Therefore, it is difficult and maybe impossible, to translate 
small peptide modifications to a correct modeled MHC-peptide-TCR structure. 
 
Advantages of a combined approach 
In a multidisciplinary methodology, we took advantage of the possibilities of both 
modeling and synthetic chemistry in order to understand the immunological 
implications of peptide modification, and these results were again used for 
validation of the molecular explanations. The predictions based on the model, 
concerning the amino acid side chains that projected out of the MHC binding groove, 
were presumably correct, since the same predictions were made earlier based on T 
cell activation and MHC binding assays using alanine substitutions.12 In this case, 
however, using the MHC-peptide model can limit the amount of peptides that need 
to be synthesized and tested. Visualization in the model of the position of the peptide 
N-terminus and the first MHC anchor, combined with knowledge from organic 
chemistry regarding N-terminal glutamine cyclization, led to the successful design of 
the N-terminally acetylated peptide (Chapter 2). The feature of peptoid-peptide 
hybrid flexibility was approached in a chemical way, by comparing the MHC 
binding affinities with similar flexible peptides, while the knowledge that peptoid-
peptide hybrids are more flexible than peptides was first derived from crystal 
structure analysis and molecular modeling.13,14 Summarizing, it was perceived that 
the homology model could give additional insight, confirmed by crystal structures, 
into peptide-MHC binding, but that this cannot be a substitute for biochemical MHC-
peptide binding assays. 
 
Recognition of the MHC-peptide complex by the TCR is difficult to characterize, 
since it is complicated to measure unambiguously. We did not have access to a 
binding assay of isolated TCRs with peptide-MHC complexes, so we measured T cell 
proliferation as an outcome of engagement of the TCR with the peptide-MHC 
complex (Chapter 5). However, absence of T cell proliferation does not necessarily 
mean absence of TCR recognition. A direct correlation between peptide structure and 
changed interactions with the TCR, was therefore not possible. Instead, relationships 
between peptide structure and T cell activation in vitro were investigated. Without a 
molecular model of the TCR, but with the possibility to synthesize tailor made 
modified peptides for direct comparison, it was possible to interpret data on T cell 
proliferation by MHC bound modified peptides. 
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Structure-based design of  
immunomodulating peptidomimetics 
 
Many attempts have been made to relate the degree of T cell activation to kinetic 
parameters, such as the dissociation rate or half life, or to the affinity of the MHC-
peptide complex for the TCR. Contradictory results suggested that even if a 
correlation was found, this might not be generally applicable (reviewed by Baker et 
al.).15 Also correlations between structural differences and the agonistic or 
antagonistic effect were not clear. Induced fit as defined by structural adaptations of 
the TCR to a modified peptide, was observed in crystal structures of MHC-peptide-
TCR complexes.16,17 However, it was difficult to relate these differences in the MHC-
peptide-TCR interface to the large difference in T cell activation in vivo,16,18 although 
Baker et al. could discriminate between an agonistic and an antagonistic peptide by 
close inspection of the altered interaction with the TCR in the crystal structures.15 
 
The limited understanding of what triggers a TCR has hampered the design and 
application of altered peptide ligands (APL), which cause an altered T cell response 
due to a modified interaction with the TCR. Most APLs have been designed in trial 
and error approaches, because predictive parameters regarding the relation between 
peptide structure, binding strength, and kinetics on the one hand, and T cell 
stimulatory effect on the other hand can only be obtained with great difficulty. 
Despite this demanding generation of APLs, successful application in experimental 
autoimmune disease animal models led to the initiation of clinical trials surveying 
APL immunotherapy in MS patients.19,20 However, these studies were terminated 
because of serious side effects. Partly, the side effects were inherent to the APL 
working mechanism, but to some extent they might be overcome with better APL 
design.21 This stresses the importance of acquiring insight into the structural aspects 
determining the initial event of T cell activation. We have tried to combine the 
current knowledge that was available on T cell activation, with the structural 
information gained on MHC-peptide-TCR interaction, to rationalize the design of 
APLs (Chapter 6). Peptidomimetic building blocks and altered amino acid residues 
based on posttranslational modifications were incorporated in order to apply desired 
alterations. However, no advantage could be obtained from the tailor made 
peptidomimetics, since it is not clear at the molecular level in which way a peptide 
should be modified in order to achieve the desired T cell activation and therapeutic 
activity. 
 
 
Structural features of modified peptides 
 
Throughout this thesis the structure of a modified peptide or peptidomimetic was 
related to MHC binding, recognition by the TCR, and finally to the outcome of T cell 
activation. Although structure-activity relationships could be deduced regarding 
MHC binding and T cell proliferation, no such rules were apparent regarding the 
Chapter 7 
106 
therapeutic behavior of the compounds in vivo. It must be kept in mind that only 
two or three compounds per modification type were studied, and that the 
conclusions may only apply to this particular system of RT1.BL-gpMBP72-85-Z1a. 
 
Peptoid-peptide hybrids 
We synthesized peptidomimetics in which TCR contact residues at positions 2, 5, and 
8 were replaced by peptoid residues. In a peptoid residue the side chain has shifted 
one atom position to the left, i.e., towards the N-terminus.13 As a result, the backbone 
nitrogen atom has no longer a hydrogen atom available for a hydrogen bond to the 
MHC (Chapter 4).6 In the peptoid-peptide hybrids presumably at position 2 a 
conserved hydrogen bond, and at position 5 a non-conserved hydrogen bond was 
disrupted, while no such hydrogen bond was present at position 8. The loss of a 
hydrogen bond close to an MHC anchor residue could have significant consequences 
for MHC binding affinity, as the initial formation of this hydrogen bond could help 
to orient the peptide MHC anchor residue.22 Loss of a hydrogen bond may result in a 
less tight local binding of the peptoid-peptide hybrid to the MHC molecule. This 
diminished binding is favorable for the local backbone reorientation, necessary for 
prevention of steric hindrance of the peptoid side chain with the MHC molecule 
(particularly at positions 2 and 5). Changes in the MHC-peptide interaction, for 
example by replacement of an MHC anchor residue can influence T cell recognition, 
possibly by this reorientation of the peptide structure or due to induced differences 
in the MHC surface exposed to the TCR.23 
 
The peptoid side chains are expected to bend out of the MHC binding groove, 
towards the TCR. Although the chemical nature of the side chain is unaltered, the 
length of the distal part of the peptoid side chain projecting out of the MHC binding 
groove and possibly also the direction of the side chain might be changed compared 
to the original amino acid side chain. It was shown before that a TCR specific for an 
agonistic peptide, interacted with an antagonistic peptide with a shorter side chain 
(alanine versus proline in agonistic peptide), resulting in a gap in the interface 
between TCR and peptide.15 In our case, the WT specific T cell clone did not 
proliferate in response to the peptoid-peptide hybrids (Chapter 5). Also a polyclonal 
WT specific T cell population showed no proliferation in response to the peptoid-
peptide hybrids. However, absence of proliferation does not necessarily mean 
absence of interaction of the MHC-peptoid-peptide hybrid complex with the TCR, 
which could be the case if the peptoid-peptide hybrids acted as antagonists. 
Nevertheless, this possibility was rejected because these compounds were unable to 
inhibit WT induced T cell proliferation in vitro, the typical feature of antagonistic 
peptides. Instead of recognizing the distal part of the peptoid side chain, it was 
shown that peptoid-peptide hybrid specific T cells, expanded after peptoid-peptide 
hybrids immunization, were sensitive to alterations in the peptoid-peptide hybrid 
backbone structure that was exposed to the TCR (Chapter 5). 
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Minimally modified peptides 
Centrally in the peptide (at position 5), the peptide was slightly modified by 
exchanging the arginine residue for a citrulline or ornithine residue. These 
replacements did not influence MHC binding, but instead, large effects on T cell 
recognition were found (Chapter 5). Although only one atom was changed, WT 
reactive T cells did not recognize the citrulline containing peptide. No crossreactivity 
for these modified peptides between WT, citrulline, and ornithine peptide reactive T 
cells was observed, despite the similarity. Maverakis et al. assumed that for 
recognition of peptide AcMBP1-9 the TCR does not contain a pocket which solely 
interacts with the guanidinium group of the original arginine amino acid residue.24 
Our results suggest the opposite, i.e., that there is highly specific recognition in TCR 
pockets interacting with peptide TCR contact residues. The lack of crossreactivity 
could be due to unfulfilled hydrogen bonding and/or salt bridge formation in this 
TCR pocket, as these modified peptides showed distinct hydrogen bonding features 
(Chapter 5). Instead, WT, citrulline, and ornithine peptide reactive T cells all 
recognized a peptide containing glycine at position 5 (unpublished data). 
Apparently, these T cells recognized side chains that were smaller than the side 
chains in the immunizing peptide, but only those side chains incapable of hydrogen 
bond formation. 
 
Glycopeptides 
Replacement of the TCR contact residue amino acid at position 2 by a galactosylated 
amino acid residue, only slightly decreased the MHC binding affinity (Chapter 5). 
This might be due to a combination of steric hindrance and high flexibility of the 
galactosylated side chain. At position 8, amino acid replacement with a 
galactosylated amino acid residue did not influence MHC binding capacity. The 
latter side chain resembled the original side chain more closely and was also not as 
large as the glycosylated side chain introduced at position 2. Both WT specific 
monoclonal and polyclonal T cells did not recognize the glycosylated peptides 
(Chapter 5). Apparently, the TCR of the WT specific T cells could not accommodate 
to the enlarged side chain. T cells specific for either one of the glycopeptides did not 
respond to the WT peptide. This may be explained in analogy to the non-
responsiveness of WT specific T cells to the peptoid-peptide hybrids; the TCR could 
not adjust to the gap resulting from the absence of the sugar residue. Also, peptides 
with a glycine residue at position 2 or 8, were not recognized by the corresponding 
glycopeptide specific T cells (unpublished data), indicating that recognition of the 
sugar residue and the amino acid side chain at those positions were of crucial 
importance for recognition of the glycopeptides. Moreover, T cells specific for the 
glycosylated peptides recognized the sugar part and the amino acid residue in a 
combined manner, with high specificity for the sugar residue.25-30 
 
Cyclized peptides 
This thesis started with the study of undesired N-terminal cyclization that occurred 
in peptide gpMBP72-85 (Chapter 2). N-terminal acetylation improved both MHC 
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binding and T cell proliferative capacity. The improved MHC binding could be 
attributed to the availability of the first peptide amino acid side chain for binding as 
an MHC anchor, that otherwise would have cyclized with the peptide N-terminus. In 
addition, new interactions of the acetyl group with the MHC molecule could account 
for the improved MHC binding affinity. The improved T cell proliferation can result 
from the higher concentration of MHC-peptide complexes on the APC. Additionally, 
the higher T cell stimulatory capacity may also be the consequence of an altered 
interaction with the TCR. In Chapter 5 we concluded that the TCR might contact the 
peptide backbone at positions 2, 5, and 8, and this could possibly also occur with the 
N-terminal acetyl group. 
 
Tselios et al. have introduced cyclization of peptide amino acid side chains on 
purpose with the intention to design stable immunomodulatory peptides.31-34 
Because NMR and modeling studies revealed that the preferred conformation of 
peptide gpMBP72-85 in isolation (not bound to MHC) was cyclic, the side chains of 
amino acid residues lysine at position 2 and glutamic acid at position 9 were 
connected via an amide bond.31 Cyclization was also applied to other peptides,33,34 
and all cyclized peptides exhibited the same, or slightly less, activity as the 
corresponding linear peptide. The authors reasoned that these peptides bound in a 
cyclic conformation to the MHC class II molecule.31 However, it is confirmed by 
crystal structures that peptides bind to MHC class II molecules in an extended 
polyproline type II twist,35 and that glutamic acid at position 9, that is used for the 
cyclization, constitutes the main MHC anchor in gpMBP72-85.3,12 
 
Furthermore, we synthesized the above described peptide. In a pilot experiment, we 
were unable to reproduce the EAE inductive effect of the cyclic WT peptide, shown 
by Tselios et al.31 (unpublished data). No MHC binding affinity for the MHC class II 
molecules RT1.BL or RT1.DL could be detected, indicating a large affinity loss (IC50 > 
256 µM, unpublished data). In addition, encephalitogenic T cell clone Z1a, that is 
generated using the gpMBP protein and specific for the linear WT peptide, only 
showed weak proliferation to the cyclic WT peptide at very high concentrations 
(unpublished data). This could be caused by undetectable contamination with linear 
WT impurities of as little as 0.025% in the cyclic WT peptide sample. As we used a 
synthesis procedure different from that of Tselios et al.,31 the purity of the cyclic 
compound might be better. It could be possible that a contamination with the linear 
WT peptide accounted for the EAE induction reported by the authors, since it was 
shown that even very small doses (2 µg or even lower) of this peptide can induce 
EAE.36,37 Besides contamination, an explanation for the in vivo activity of the cyclic 
peptides, reported by Tselios et al.31-34 might be that the cyclic bond was cleaved by 
proteases. Although it is assumed that this does not occur, it is also recognized that 
not all proteases in antigen processing are known yet.38 In summary, our 
interpretation of the data provided by these authors is that it is unlikely that 
cyclization produces APLs with immunomodulatory activity, since all cyclic peptides 
exhibited approximately the same activity as the corresponding linear peptide. 
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Conclusions and future perspectives 
 
In this thesis, the influence of peptide modification on interactions in the MHC-
peptide-TCR complex was studied. Where chemistry and immunology meet, a 
combination of modeling techniques and structural analysis, organic synthesis, and 
immunological assays provided a powerful tool for definition of structure-activity 
relationships. This knowledge of molecular interaction can be applied for design of 
peptide based tumor vaccines that require an improved MHC binding capacity.39 
However, this could not be extended to the prediction of immunomodulatory 
peptides for therapeutic intervention in autoimmune disease. It was possible to relate 
features such as MHC binding and T cell proliferation to alterations in interactions of 
the peptide with the MHC and TCR molecules, although we did not have crystal 
structures to confirm this. A better understanding of the molecular interaction is 
important to unravel the relation between peptide structure and in vivo behavior. 
Possibly, the structure-activity relationships of molecular interaction in the MHC-
peptide-TCR complex could be combined with structure-activity relationships of 
affinity/kinetics that were established in individual cases, to find better and 
generally applicable correlations. Moreover, the emerging availability of MHC-
peptide-TCR crystal structures and binding studies in combination with the 
techniques used in this thesis, are expected to shed light on this issue. 
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Achtergrond 
 
T-celimmunologie 
Het afweer- of immuunsysteem beschermt ons tegen ziektes veroorzaakt door micro-
organismen. Ook zorgt het voor het opruimen van dode cellen en tumoren. T-cellen, 
een soort witte bloedcellen, spelen bij deze afweerreactie een belangrijke rol. De T-cel 
herkent bepaalde antigenen van een bacterie of virus. Deze herkenning leidt tot een 
immuunreactie die gericht is op het onschadelijk maken van de ziekteverwekker. 
Wanneer een dergelijke immuunreactie optreedt tegen gezond lichaamseigen weefsel 
kan een auto-immuunziekte het gevolg zijn, zoals reumatoïde artritis (reuma) of 
multiple sclerose (MS). 
 
De T-cel heeft op zijn oppervlak een receptor, de T-cel receptor (TCR). Het antigeen 
zoals een T-cel dat herkent met zijn TCR, is een fragment van een eiwit, een peptide, 
dat bestaat uit aminozuren. Dit peptide is gebonden aan een molecuul van het major 
histocompatibility complex (MHC), dat op het oppervlak zit van een antigeen 
presenterende cel (APC). De T-cel ‘scant’ met zijn ‘antenne’ (TCR) het antigene 
peptide, dat op een ‘dienblad’ (MHC) gepresenteerd wordt door de APC (zie Figuur 
1, Hoofdstuk 6). De binding in het MHC-peptide-TCR-complex bestaat uit 
zoutbruggen, waterstofbruggen (interacties via waterstofatomen) en hydrofobe 
interacties (het aan elkaar plakken van ‘vette’ atoomgroepen). In het oppervlak van 
zowel het MHC als de TCR zitten holtes waarin de zijketens van de aminozuren van 
het peptide binden. In Figuur 1 van Hoofdstuk 6 zijn de drie aminozuren van het 
peptide weergegeven die aan de TCR binden, de TCR-contactresiduen. Door 
interactie van het MHC-peptide-complex met de TCR kan de T-cel geactiveerd raken. 
Deze stimulatie van T-cellen is de start van een immuunreactie. Als gevolg van 
stimulatie kan de T-cel onder andere signaaleiwitten gaan produceren en 
prolifereren (vermeerdering via deling). 
 
Peptidenmodificatie 
De mate van activiteit van de T-cel wordt onder andere bepaald door het peptide; 
een gemodificeerd peptide geeft vaak een andere reactie van de T-cel. Verandering 
van het peptide kan optreden als gevolg van eiwitmodificatie in de cel 
(posttranslationele modificaties). Deze veranderingen in het peptide kunnen ervoor 
zorgen dat een peptide dat eerst niet herkend werd door de T-cel, nu wel voor 
stimulatie van de T-cel zorgt en op deze manier een auto-immuunziekte in gang zet. 
Anderzijds worden gemodificeerde peptiden, of altered peptide ligands (APLs), ook 
gebruikt voor specifieke behandeling in experimentele diermodellen van auto-
immuunziekten. Recentelijk zijn ook klinische studies uitgevoerd met een APL als 
geneesmiddel voor de behandeling van MS. Een specifieke behandeling met een APL 
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zou een betere therapie kunnen zijn dan de huidige therapieën bij MS, aangezien 
daarbij een groot deel van het immuunsysteem wordt onderdrukt en het niet 
specifiek ingrijpt in het ziekteproces. Helaas traden bij de APL-therapie zoveel 
bijwerkingen op, dat de studies voortijdig beëindigd zijn. Een beter ontwerp van het 
gemodificeerde peptide zou deze bijwerkingen kunnen verminderen. 
 
 
Dit proefschrift 
 
Doelstelling en methode van onderzoek 
Inzicht in de moleculaire interactie tussen MHC, peptide en TCR is van groot belang, 
omdat de specificiteit van de T-cel reactie (welk peptide activeert de T-cel en welk 
niet) en de mate van stimulatie hierdoor worden bepaald. Er is weinig bekend over 
hoe een kleine verandering in een peptide leidt tot een grote verandering in activiteit 
van de T-cel. In dit proefschrift is de invloed bestudeerd van modificatie van een 
peptide op de interactie in het MHC-peptide-TCR-complex en op de uitkomst van 
stimulatie van de T-cel, beginnend bij het molecuul (het gemodificeerde peptide) en 
eindigend in een dier (de rat). We gebruikten hiervoor een diermodel voor menselijk 
MS.1 
 
Om de interactie tussen moleculen te visualiseren hebben we een computermodel 
van MHC met peptide gebouwd (Figuur 1, Hoofdstuk 3). Hiervoor is 
gebruikgemaakt van kristalstructuren (met kristallografische technieken is de 
driedimensionale structuur van een eiwit af te leiden). Met behulp van dit 
computermodel zijn gemodificeerde peptiden ontworpen. Vervolgens zijn deze 
peptiden gesynthetiseerd, waarbij soms eerst de gemodificeerde aminozuren 
moesten worden gemaakt. De peptidenmodificatie resulteerde in enkele gevallen in 
een peptidomimeticum, een op een peptide gelijkende stof. Deze kan op maat 
gemaakt worden met precies de gewenste structuur. De gemodificeerde peptiden en 
peptidomimetica zijn getest op MHC-bindingsaffiniteit en het veroorzaken van 
proliferatie van geïsoleerde T-cellen en stimulatie van T-cellen in de rat. 
 
Eigenschappen van de gemodificeerde peptiden 
In Hoofdstuk 2 wordt beschreven dat het peptide, waarmee experimentele MS kan 
worden opgewekt in ratten, stabieler wordt en dus langer kan worden bewaard, 
wanneer een acetylgroep als bescherming wordt aangebracht op de N-terminus 
(linker uiteinde) van het peptide. De N-terminus van het peptide kan daardoor niet 
meer reageren met de zijketen van het eerste aminozuur glutamine, waarbij het 
cyclische pyroglutaminezuur ontstaat. Het geacetyleerde peptide bindt beter aan het 
MHC, geeft sterkere proliferatie van T-cellen, maar veroorzaakt niet een ernstigere 
ziekte in de rat dan het niet-geacetyleerde peptide. Er werd geconcludeerd dat 
acetylering van de N-terminus gunstig is en in de rest van het onderzoek beschreven 
in dit proefschrift, is dat dan ook steeds toegepast. 
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De zijketens van drie TCR-contactresiduen in het peptide werden één atoompositie 
naar de N-terminus (naar links) verschoven (Hoofdstuk 4). Hierbij werd 
gebruikgemaakt van peptoïde bouwstenen en deze gemodificeerde peptiden 
(eigenlijk peptidomimetica) worden peptoïde-peptide hybriden genoemd (Figuur 3, 
Hoofdstuk 1). We beschrijven de effecten van deze modificatie op de MHC-binding. 
Hiervoor gebruiken we het computermodel, informatie uit kristalstructuren en een 
groep van gemodificeerde peptiden waarvan de MHC-binding werd getest. De 
peptoïde-peptide hybriden bleken een lage MHC-bindingsaffiniteit te hebben, 
waarvoor we twee oorzaken vonden. Het vervangen van een aminozuur door een 
peptoïde bouwsteen kan ervoor zorgen dat een waterstofbrug niet meer gevormd 
kan worden. Bovendien bleken de zijketens van de peptoïde bouwstenen niet goed 
in het MHC-molecuul te passen. 
 
In Hoofdstuk 5 onderzoeken we of de T-cel de gemodificeerde peptiden en 
peptidomimetica herkent, door de proliferatie te meten. De peptoïde-peptide 
hybriden werden niet herkend door een T-celkloon die specifiek is voor het 
onveranderde peptide. Ook peptiden waarbij de TCR-contactresiduen zijn veranderd 
door eiwitmodificaties na te bootsen, werden niet herkend. Sommige van deze 
modificaties veroorzaakten slechts kleine structuurveranderingen, zoals bij de 
vervanging van een arginine aminozuur door een citrulline of ornithine aminozuur. 
Andere modificaties veroorzaakten grotere veranderingen, zoals bij het aanbrengen 
van een suikergroep. Alle gemodificeerde peptiden zorgden wel voor de stimulatie 
van T-cellen wanneer het gemodificeerde peptide werd geïnjecteerd in de rat. Deze 
T-cellen herkenden echter specifiek het gemodificeerde peptide en soms ook 
gelijkende gemodificeerde peptiden, maar niet het oorspronkelijke peptide. 
 
Conclusies en toekomstperspectief 
De multidisciplinaire onderzoeksmethode zoals beschreven in dit proefschrift, is een 
geschikte aanpak gebleken om verbanden te leggen tussen de structuur van het 
peptide en de MHC-binding en de mate van activiteit van T-cellen (Hoofdstuk 7). We 
hebben echter geen APL kunnen ontwerpen en maken, die de ziekte bij ratten kon 
verhinderen (Hoofdstuk 6), zodat het gebruikt kan worden voor specifieke therapie 
van (experimentele) auto-immuunziekten. Een belangrijk voordeel van een 
peptidomimeticum, namelijk dat die precies gemaakt kan worden zoals is gewenst, 
kan niet worden benut omdat nog onbekend is wat precies de structuur moet zijn 
van een therapeutische APL. Naar verwachting zal hier de komende jaren meer 
inzicht in ontstaan, als er meer kristalstructuren van MHC-peptide-TCR-complexen 
beschikbaar komen. Het combineren van verschillende vakgebieden, zoals hier 
beschreven, zal ook dan van groot belang zijn. 
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1Het ‘peptide’ in deze samenvatting is het peptide gpMBP72-85, dat bestaat uit aminozuren 72 
tot 85 van het cavia-eiwit guinea pig myelin basic protein. Als het gebonden is aan het MHC klasse 
II molecuul RT1.BL, wordt dit herkend door de TCR van T-cel Z1a (Hoofdstuk 1). Met ‘ziekte’ 
wordt experimental autoimmune encephalomyelitis (EAE) bedoeld, een diermodel (rat) voor MS. 
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List of abbreviations 
 
 
General 
 
APC  antigen presenting cell 
APL  altered peptide ligand 
CDR  complementarity determining region 
CFA  complete Freund’s adjuvant 
EAE  experimental autoimmune encephalomyelitis 
FCS  fetal calf serum 
Fmoc  9-fluorenylmetholoxycarbonyl 
gpMBP  guinea pig myelin basic protein 
HATU O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium 
hexafluorophosphate 
HBTU O-benzotriazole-1-yl-N,N,N',N'-tetramethyluronium 
hexafluorophosphate 
HOAt  1-hydroxy-7-azabenzotriazole 
HOBt  1-hydroxybenzotriazole 
HPLC  high-pressure liquid chromatography 
HV  hypervariable 
IC50  inhibition concentration (50%) 
IDDM  insulin-dependent diabetes mellitus 
IMDM  Iscove’s modified Dulbecco’s medium 
MBP  myelin basic protein 
MHC  major histocompatibility complex 
MS  multiple sclerosis, mass spectometry 
Mw  molecular weight 
NRS  normal rat serum 
OVA  ovalbumin 
PDB  Protein Data Bank 
PLNC  popliteal lymph node cells 
RA  rheumatoid arthritis 
SD  standard deviation 
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SEM  standard error of the mean 
SI  stimulation index 
SMPS  simultaneous multiple peptide synthesis 
TFA  trifluoroacetic acid 
TCR  T cell receptor 
WT  wild type 
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Amino acids and other building blocks 
 
Ala A alanine 
Arg R arginine 
Asn N asparagine 
Asp D aspartic acid 
Cys C cysteine 
Gln Q glutamine 
Glu E glutamic acid 
Gly G glycine 
His H histidine 
Ile I isoleucine 
Leu L leucine 
Lys K lysine 
Met M methionine 
Phe F phenylalanine 
Pro P proline 
Ser S serine 
Thr T threonine 
Trp W tryptophan 
Tyr Y tyrosine 
Val V valine 
 
Ac  acetyl 
Cit  citrulline 
Gal  galactose 
NAaa  peptoid corresponding to amino acid Aaa 
Orn  ornithine 
Pyroglu  pyroglutamic acid, pyroglutamyl 
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